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Abstract and Keywords
Dietary and gastrointestinal factors may be associated with the 
developm ent/w orsening of autistic symptoms in a subset of patients. Propionic 
acid (PPA) is a m etabolic byproduct of gut bacterial fermentation. 
Intracerebroventricular (ICV) infusions of PPA in rodents produce transient 
behavioural and biochemical changes similar to those seen in autism. The 
perm anence of the cognitive deficits associated with the PPA rodent model of 
autism was assessed using adult male rats in the Morris w ater maze (MWM). 
Following an ICV regim en of PPA or vehicle (2x/day, 7 days), rats were tested in the 
MWM (acquisition) and then one week later for reversal. On reversal day, 
perseveratory behaviours w ere assessed following 2 additional infusions. PPA-
S
treated rats displayed longer search latencies to find the platform  during MWM 
acquisition, bu t showed norm al reversal one week later. A second experiment used 
nonspatial pretraining prior to treatm ent in order to differentiate between spatial 
versus strategy deficits, and effects of stress in the MWM. Similar to the first study, 
rats treated w ith PPA on reversal day showed impairm ents in the maze, regardless 
of initial drug treatm ent. In summary, PPA treatm ent caused im pairm ents in 
cognition as m easured in the MWM, but these behavioural im pairm ents appear to 
return  to baseline after the drug treatm ent is stopped, suggesting that some effects 
of PPA may be reversible.
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1.1 Autism Spectrum Disorders
Autism spectrum disorders (ASDs) are a family of neurodevelopmental disorders 
affecting approximately 1 in 110 children (Centers for Disease Control & Prevention, 
2009). This family o f disorders is characterized by social deficits, profound language and 
communication impairments, repetitive and ritualistic behaviours, sensory disturbances, 
and altered motor activity (Arndt, Stodgell, & Rodier, 2005; DiCicco-Bloom, et al., 2006). 
As well, there is an increased occurrence of seizure disorder in individuals with ASD 
(Besag, 2004). Learning has also been shown to be disrupted in autistic individuals. 
Mostofsky et al. (2000) reported impaired ability to acquire procedural knowledge in 
autistic participants, whereas other aspects of performance on a serial response time task, 
such as judgement o f timing intervals, were no different than control children. Similarly, 
it has been shown that individuals with autism are equally able to discriminate between 
novel and familiar stimuli, while control participants were better able to discriminate 
familiar stimuli as opposed to novel stimuli (Plaisted, O’Riordan, & Baron-Cohen, 1998). 
It has been suggested that autistic individuals tend to show increased attentional focus on 
specific stimuli and that perhaps this leads to the selection of only a small subset of the 
environmental stimuli on which these individuals base their responding (Plaisted et al., 
1998). Finally, Schipul and colleagues (2011) examined the functional connectivity in the 
brains of ASD patients and suggested the possibility that the impairments in the ability of 
individuals with autism to rapidly adapt during learning could be the result of cortical 
underconnectivity. Together, these findings point towards impaired learning in ASD, with 
an emphasis on increased attention to specific stimuli and lack of ability to adapt to novel 
stimuli.
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Beyond the behavioural aspect of the disorder, there are also consistent 
developmental abnormalities seen in the brains of individuals with autism. Specifically, 
during the first few years of life, children with autism show increased brain sizes 
compared to controls (Bauman & Kemper, 2005; Herbert, 2005; Herbert et al., 2005).
This increase in overall size appears to be linked to a disproportionate increase in white 
matter that occurs beginning shortly after birth arid returns to control levels after several 
years, such that only younger autistic brains are larger than controls. The increase in white 
matter, as well as the nonuniform pattern in which this occurs, appears to be suggestive of 
postnatal pathology (Herbert, 2005). Similarly, examination of brain tissue of ASD 
patients has shown evidence of an innate neuroinflammatory response, including activated 
microglia, reactive astrogliosis, and increased levels of proinflammatory cytokines found
in the cerebral spinal fluid of these individuals (Vargas, Nascimbene, Krishnan,
\
Zimmerman, & Pardo, 2005). While the number of neurons in the brains of autistic 
patients appears to be the same as what is seen in healthy control brains, an increase in 
neuronal density is observed in certain areas, including neocortical, limbic, and cerebellar
v
areas (Cody, Pelphrey, & Piven, 2002; Courchesne & Pierce, 2005).
Studies have shown that concordance rates for autism in monozygotic twins are 
between 60% and 90%, as opposed to 0-10% concordance in dizygotic twins (Bailey et al., 
1995; Steffenburg et al., 1989). Similarly, there is also a discrepancy in the severity of the 
disorder in monozygotic twins. This incomplete concordance rate, along with the 
increasing prevalence o f autism over the past several decades, has suggested the 
possibility o f an environmental contribution to the pathogenesis of autism. Many 
epidemiological models have focused on potential neonatal or early postnatal
environmental factors, such as exposure to valproic acid (Ingram, Peckham, Tisdale, & 
Rodier, 2000),' ethanol (Arndt, Stodgell, & Rodier, 2005), and thalidomide (Narita, Kato, 
Tazoe, Miyazaki, Narita, & Okado, 2002). Also, exposure to several types of metals or
i
viral infections have been implicated as potential factors (Curtis, Hood, Chen, Cobb, & 
Wallace; 2010; Fatemi, Cuadra, El Fakahany, Sidwell, & Thuras, 2000). Based on this,
ASD is now considered to be a whole-body condition involving immune, digestive, and
/ /
metabolic dysfunction, all of which can be triggered by these environmental factors in 
genetically susceptible individuals (Ashwood & Van de Water, 2004; Chauhan & 
Chauhan, 2006; Herbert et al., 2006; Horvath & Perman, 2002).
Gastrointestinal (GI) disturbances have also been reported in autism, with findings 
that up to 59% of autistic patients suffer from some sort of GI dysfunction, including
diarrhea, constipation, bloating, and gastroesophageal reflux (Adams, Johansen, Powell,
' ' . \
Quig, & Rubin, 2011; Ming, Brimacombe, Chaaban, Zimmerman-Bier, &Wagner, 2008).
Reports of the development and/or worsening o f autistic symptoms following such
gastrointestinal abnormalities (Adams, Johansen, Powell, Quig, & Rubin, 2011; Horvath,
Papadimitrou, Rabsztyn, Drachenberg, & Tildon, 1999), the ingestion of certain types of
i carbohydrates and dairy products, and pediatric infections for which antibiotics are
administered (Goodwin, Cowen, & Goodwin, 1971; Finegold, Song, & Liu, 2002; Fallon,
2005) also provide some support for the involvement of environmental agents in the
development o f autism in susceptible individuals.
1.1.1 Gastrointestinal and Digestive Dysfunction
GI difficulties are present in a large subset o f children with ASD. These 
abnormalities include various different symptoms and have been shown to be present
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significantly more in autistic children than normally developing children (Adams et al., 
2011). Finegold et al. (2002) analyzed the fecal flora from children with late-onset autism 
as well as healthy control children and found higher levels of Clostridium and 
Ruminococcus species, as well as a greater number of these types of species, in the stools 
of autistic children. Specifically, Finegold and colleagues (2002) reported the presence of 
nine species of Clostridia found in ASD patients that were not found in controls, whereas 
there were only three species found in controls that were not present in individuals with 
ASD. Clostridia are the principal bacteria that produce enterotoxins and neurotoxins.
This, along with their high metabolic activity, allows them to produce potentially high 
levels of toxic metabolites which can influence the central nervous system (Finegold et al., 
2002). Treatment with antibiotics, rather than eradicating these types of bacteria, which
can be difficult due to the spore-forming nature o f Clostridia, can in fact promote
\
overgrowth o f certain bacterial species (Finegold et al., 2002). This is an important 
finding given the putative association between antibiotic use and the occurrence of late- 
onset autism (Parracho, Bingham, Gibson, & McCartney, 2005). Recently, Finegold and 
colleagues (2010) identified two additional types of enteric bacterial species that are 
present in significantly higher numbers in children with ASD compared to controls. These 
two types of bacteria, Desulfovibrio species and Bacteroides vulgatus, also produce PPA 
and other short-chain fatty acids (SCFAs) in the digestive system. Together, these findings 
point towards significant alterations in the intestinal flora of ASD patients, which may be 
involved in the development of the disorder.
1.2 Propionic Acid
Propionic acid (PPA) is a short-chain fatty acid that is naturally present in the
digestive systems of many organisms. This compound serves an important function in the 
gastrointestinal ecosystem, including anti-bacterial, anti-fungal, and anti-inflammatory 
protective effects, as well as playing a role in some obesity-related diseases by lowering 
cholesterol and increasing the duration of satiety (Al-Lahham, Peppelenbosch, Roelofsen, 
Vonk, & Venema, 2010; Boden, 2008; Davidson, Sofos, & Branes, 2005; Levison, 1973). 
Conversely, PPA also has several negative effects in the body, such as contributing to 
gingival inflammation (Niederman, Zhang, & Kashket, 1997), reducing antioxidant 
capacity (MacFabe et al., 2008), and interfering with fatty acid metabolism when present 
in elevated levels (Akman, Imamoglu, Demirkol, Alpay, & Ozek, 2002; Thomas, Foley, 
Mepham, Tichenoff, Possmayer, & MacFabe, 2010).
PPA is a metabolic by-product of fermentation in the gut. Interestingly, 
approximately 20% of the PPA present in the body is produced by ASD-associated enteric 
bacteria (i.e., Clostridia, Desulfovibrio, etc.), as a result of such fermentation (Finegold et 
al., 2002; Finegold et al., 2010). PPA is a weak organic acid and is present in the blood in 
both ionized and non-ionized forms, which allows it to gain access to the central nervous 
system (CNS) by readily crossing lipid membranes such as the gut-blood barrier and the 
blood-brain barrier (Niederman, Zhang, Kashket, 1997; Maurer, Canis, Kuschinsky, & 
Duelli, 2004). Once PPA, as well as other short-chain fatty acids, have become 
incorporated into the systemic or CNS environment, they have been shown to affect 
several different physiological processes. These widespread effects include cell signaling 
(Nakao, Moriya, Furuyama, Niederman, & Sugiy, 1998), mitochondrial function (Wagner, 
Bayir, Ren, Puccio, Zafonte, & Kochanek, 2004), lipid metabolism (Hara, Haga, Aoyama, 
& Kiriyama, 1999), neurotransmitter synthesis and release (DeCastro, et al., 2005),
6
immune function (Le Poul et al., 2003), modulation of gene expression (Suzuki, Nagao, 
Tokunaga, Katayama, & Uyeda, 1996), and gap junctional gating (Rorig, Klausa, & Sutor, 
1996). All of these effects suggest that PPA could be involved in the various aspects of 
ASD. ■. ■ . . ■
1.2.1 Propionic Acid & Autism
There are several metabolic conditions that are linked with elevated levels of PPA, 
including propionic acidemia (Brusque et al., 1999; Wajner, Latini, Wyse, & Dutra-Filho, 
2004). In this disorder, levels of PPA are constantly elevated in the blood due to disrupted 
metabolism of the compound. Propionic acidemia is characterized by developmental 
delay, seizure disorder, and GI difficulties, all of which are reminiscent of autistic 
symptomatology (Brusque et al., 1999; Kaya et al., 2008), indicating that accumulation of 
PPA can elicit autistic-like traits. \
The ability of PPA to induce autistic-like symptoms, as well as the elevated levels 
of PP A-producing bacteria found in the intestinal tracts of ASD patients have lead to the 
establishment of the PPA rodent model of autism.Mntracerebroventricular (ICV) infusions 
of PPA and related enteric short-chain fatty acids (i.e., butyrate, acetate) directly into the 
lateral ventricle of adult Long-Evans rats have led to behavioural findings including bouts 
of hyperactivity, repetitive and stereotypical movements, object fixation, social 
. impairments, kindling of seizures, caudate spiking, and perseveration, all of which are 
consistent with traits seen in ASD (MacFabe et al., 2007; MacFabe et al., 2008; MacFabe, 
Cain, Boon, Ossenkopp, & Cain, 2011; Shultz et al., 2008; Shultz et al., 2009). Similarly, 
neuropathological and biochemical findings from this model give evidence of an innate 
neuroinflammatory response, including reactive astrogliosis and activated microglia, as
well as an increase in oxidative stress markers and a reduction in glutathione (MacFabe et 
al., 2007; MacFabe et al., 2008). These data are again consistent with the innate immune 
response and the increased oxidative stress found in ASD autopsy data (Chauhan,
Chauhan, Brown, & Cohen, 2004; Vargas et al., 2005; Chauhan & Chauhan, 2006; James 
et al., 2006). Finally, the PPA rodent model of autism has provided evidence of altered 
lipid profiles, similar to what is seen in the human disorder (Bell, Sargent, Tocher, &
Dick, 2000; Clark-Taylor & Clark-Taylor, 2004). The alterations seen in the model 
include both increases and decreases in certain species of fatty acids (e.g. increases in 
saturated fatty acids, decreases in monounsaturated fatty acids, and alterations in the 
balance of the omega fatty acids), as well as altered carnitine and acylcamitine profiles. 
These alterations have been shown in lipids involved in cell-to-cell signaling, membrane
fluidity, and mitochondrial energy metabolism (Thomas et al., 2010).
\ '
As mentioned, seizure disorder is often comorbid with ASD (Besag, 2004; Sansa et 
al., 2011). Autism is associated with an increased risk of epilepsy, which includes a 
variety of seizure types, and 6-60% of autistic patients demonstrate epileptiform 
abnormalities on electroencephalogram (EEG; Hara, 2007; Sansa et al., 2011). In 
addition, the prevalence o f seizure disorder in autism increases with several factors, one of 
which is decreased intellectual disability. The mechanisms involved in the increased 
occurrence of seizure disorder in ASD are relatively unknown. Several PPA-dependent 
mechanisms could produce seizure, including interruptions in gap junctional 
communication, GABAergic inhibition, and potentiation of glutamate receptors (MacFabe 
et al., 2007). Taken together, it has been shown that seizure is a common aspect of ASD 
and thus it is important to consider seizure activity in the PPA rodent model.
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1.3 Clinical Fluctuation in Autistic Symptoms 
While it is generally agreed upon that improvement may be seen in certain cases of 
ASD, this type of “recovery” has not been extensively studied. This controversial concept 
of worsening and improvement in autism has received attention both anecdotally and 
experimentally (Mundy & Crowson, 1997; Dawson & Zanolli, 2003; Fein, Dixon, Paul, & 
Levin, 2005). However, there are currently no suggested putative mechanisms by which 
such fluctuations might be occurring, nor are there biomarkers that might help elucidate 
the nature of these fluctuations. Reports from parents with autistic children have indicated 
that there is a link between ingestion of certain dietary components, such as refined 
carbohydrates or dairy products, which are often craved by these patients, and the 
worsening of autistic symptoms (Jyonouchi, Sun, & Itokazu, 2002). Conversely, 
improvements in behaviour, social abilities, and GI function have been observed 
empirically in some patients following treatment with antibiotics, administration of 
antioxidants, facilitation of mitochondrial function, or changes in diet (Horvath et al.,
1999). Herbert and colleagues (2006) noted that in autistic individuals there is substantial
\
intra-individual variability in both the nature and severity o f the characteristic symptoms, 
which is not necessarily a result of treatment. This variability has been found to occur 
over the short, medium, or long term. These changes in autistic symptomatology suggest 
that the idea of “recovery” is an area that should be further explored. The concept of 
“recovery” must be approached with caution, as there is no generally accepted definition 
at this point in time. Helt et al. (2008) describe “recovery” as the loss of the behavioural 
characteristics of ASD. They do not claim' however, that a child must be labeled
/ /
“normal” in order to be considered “recovered”. Thus “recovery”, for the purposes of the 
present studies, will be used to refer to a return to baseline levels of performance.
1.4 Present Studies
Autism is a complex disorder with multiple factors contributing to its development 
(Herbert el al., 2006). It has been suggested that ASD symptoms can follow a pattern of : , 
waxing and waning, depending on such external factors as dietary intake, GI disturbances, 
or treatment with antibiotics, in a subset of patients. Given the association between gut 
bacteria, the production o f SCFAs, and autistic symptomatology, it is necessary to look at 
the time course of PPA-induced behavioural and neuropathological characteristics in order 
to examine this concept of clinical fluctuation in an animal model. PPA has been shown 
to cause alterations in several aspects of cognition, including learning and memory
(Brusque et al., 1999; MacFabe et al., 2007; MacFabe et al., 2011; Shultz et al., 2009).
\
Given the known impairments in both learning and memory experienced by individuals
J
with autism, including deficits in visual recognition memory (Boucher & Warrington, 
1976), it was important to investigate the effects of PPA on learning and memory in the 
rodent model. Recently, MacFabe and colleagues (2011) showed an increased amount of
time spent interacting with a specific, preferred object by PPA-treated rats compared to
■ ■ r
controls. Similarly, these same PPA-treated rats spent less time than controls approaching
and interacting with a novel rat in an open field, when given the choice between a novel
 ̂ •
i
rat and a hovel object. It was concluded that PPA treatment can cause animals to 
perseverate on a specific object, which is consistent with the repetitive and ritualistic 
behaviours seen in ASD patients (Sasson, Turner-Brown, Holtzclaw, Lam, & Bodfish, 
2008). The present experiments were designed to assess the long-term effects of PPA on
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the cognitive abilities of adult male rats, as measured in the Morris water maze. The 
Morris water maze is a common test of spatial learning and memory in behavioural 
neuroscience. Rodents are given a certain number of training trials in a circular pool filled 
with water to learn the location of a hidden platform, based on visual cues around the 
room. This is called acquisition of the maze and occurred immediately following infusion. 
Given that the half life o f  PPA has been shown to be between 18 and 57 minutes when 
administered to rats, it was appropriate to have behavioural testing follow infusion 
immediately (Brusque et al., 1999). The animals are then tested for reversal of the maze, 
where they are again given the same number of training trials to learn a new location of 
the hidden platform. Shultz et al (2009) showed similar perseverative behaviour measured 
in the water maze, as a result of PPA treatment. Animals persisted in returning to the
initial location of the platform and were unable to learn a new location.
\
Since PPA has been shown to have cognitive effects in the form of perseveration of 
behaviour (MacFabe et al., 2011; Shultz et al., 2009), and biochemical and 
neuropathological changes have been observed following PPA infusion (MacFabe et al., 
2007; Thomas et al., 2010), it is necessary to examine the lasting effects of PPA on 
cognitive functioning over time. Chapter 2 examines the effects of repeated, daily ICV 
infusions of PPA on the animals’ ability to acquire and subsequently reverse the maze, 
either with or without the compound present. It was hypothesized, based on previous
I
studies, that the animals would have impairments in reversing the maze (i.e., learning a 
new location of the hidden platform) when under the influence of PPA. Another purpose 
of the study was to investigate the time course of performance changes following 
discontinuation of PPA treatment. In light of the findings in Chapter 2, studies in Chapter
3 investigated the effects o f nonspatial pretraining on the animals’ performance in the 
water maze. Nonspatial pretraining is a technique designed to allow animals to acquire the 
behavioural strategies that are necessary to solve the water maze (i.e., the hidden platform 
is the sole refuge in the maze, the animal must swim away from the wall to find the 
platform, etc.), without learning a specific spatial location of the platform. This technique 
has been shown to help discriminate between the influences of behavioural strategies 
learning and the cognitive spatial learning components in the maze (Cain, 1998; Hoh & 
Cain, 1999), as well as decrease the stress experienced by the animals in the maze 
(Holscher, 1999). Rodents generally experience a strong stress response in the maze that 
increases with experience (e.g. consecutive trials), and stress can impair performance in 
this task (Cain, Boon, & Corcoran, 2006; Holscher, 1999). Not only does stress influence 
cognitive functioning with regards to memory acquisition and long-term storage, but it has 
also been shown to affect memory retrieval (de Quervairi, Roozendaal, & McGaugh,
1998). Thus, stress has a large impact on water maze performance, as the task is designed
to measure spatial learning and memory. Reducing the level of this stress response is in
\
attempt to eliminate the possible confounding effects of stress on memory.
It was predicted that nonspatial pretraining would improve water maze 
performance by allowing the animals to learn the necessary strategies prior to drug 
administration. PPA-treated animals were expected to show persisting deficits in maze 
performance, due to the diverse effects of PPA on cognition (Brusque et al., 1999; 
MacFabe et al., 2007). Previous studies have shown alterations in a variety of 
physiological processes caused by PPA, such as effects on cell signaling (Nakao, Moriya, 
Furuyama, Niederman, & Sugiy, 1998), neurotransmitter synthesis and release (DeCastro,
12
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et al., 2005), mitochondrial function (Wagner, Bayir, Ren, Puccio, Zafonte, & Kochanek, 
2004), lipid metabolism (Hara, Haga, Aoyama, & Kiriyama, 1999), modulation of gene 
expression (Suzuki, Nagao, Tokunaga, Katayama, & Uyeda, 1996), and gap junctional 
gating (Rorig, Klausa, & Sutor, 1996). All of these physiological effects can potentially 
interfere with cognitive processes that are necessary in learning in memory. Brusque and 
colleagues (1999) found impaired learning in an experimental rodent model of propionic 
acidemia, as measured in a shuttle-avoidance task, as well as deficits in the animals’ 
ability to habituate to a novel environment. Similarly, there is a robust finding of a PPA- 
induced innate neuroinflammatory response and phosphorylation of CREB in the model, 
specifically in the hippocampal region (MacFabe et al., 2007; MacFabe et al., 2008), 
which plays a large role in spatial learning and memory (O’Keefe & Nadel, 1978; Morris, 
Garrud, Rawlins, & O’Keefe, 1982). The disruption in this area, as well as the overall 
effects on CNS functioning as a result of PPA treatment suggest that spatial learning 
deficits should be expected. However, it has been shown that animals who have received 
nonspatial pretraining prior to sustaining hippocampal damage are able to learn the maze 
as well as controls (Winocur, Moscovitch, Fogel, Rosenbaum, & Sekeres, 2005). This 
suggests that a detailed analysis of water maze performance following pretraining is a 
valuable way to learn more about the effects of ICV PPA in the rodent model of autism.
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Chapter 2:
Examining the Time-Course of Propionic Acid-Induced Performance Deficits in
the Morris Water Maze
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 ̂ i. : 2.1 Introduction
Autism spectrum disorders are a family of lifelong disorders characterized by 
communication deficits, social impairments, and restricted and/or ritualistic behaviours 
(Arndt, Stodgell, & Rodier, 2005; DiCicco-Bloom et al., 2006). A subset of patients also 
present with co-morbidities, such as gastrointestinal disturbances and seizure disorder 
(Besag, 2004; Horvath, Papadimitrou, Rabsztyn, Drachenberg, & Tildon, 1999). 
Additionally, human autopsy studies of patients with autism have reported central nervous 
system (CNS) immune activation in the form of increases in reactive astrogliosis and 
activated microglia (Vargas, Nascimbene, Krishnan, Zimmerman, & Pardo, 2005).
There have been large increases in the number of children being diagnosed with 
ASD. Currently, approximately 1 in every 110 children is given a diagnosis of ASD,
which is a substantial increase from previous years (Centers for Disease Control &
\
Prevention, 2009). Research has shown that these increases are likely not completely due 
to improved diagnostic criteria or increased awareness of the disorder alone (Newschaffer, 
Faib, & Gurney, 2005; Rutter, 2005; King & Bearman, 2009).
Research has shown that there is a strong genetic contribution to ASD. However, 
lack of complete concordance rates amongst monozygotic twins, along with notable 
variation in severity of the disorder, even when both twins are affected, suggest that
¡genetics are not solely responsible for the disorder (Hu, Frank, Lee, & Quackenbush,
j
2006). Many environmental factors have been implicated in this disorder, which is now 
widely considered to be a condition involving immune, digestive, and metabolic 
dysfunction, all of which can be triggered by these environmental factors in genetically 
susceptible individuals (Ashwood & Van de Water, 2004; Chauhan & Chauhan, 2006;
22
Herbert et al., 2006; Horvath & Perman, 2002). Several of these putative environmental i;- 
contributors have been studied, including pre- and postnatal exposure to valproic acid 
(Ingram, Peckham, Tisdale, & Rodier, 2000), ethanol (Arndt, Stodgell, & Rodier, 2005), 
and thalidomide (Narita, Kato, Tazoe, Miyazaki, Narita, & Okado, 2002). Similarly, 
exposure to certain metals and viral infections has been implicated (Curtis, Hood, Chen, 
Cobb, & Wallace; 2010; Fatemi, Cuadra, El Fakahany, Sidwell, & Thuras, 2000;
Patterson, 2009). Beyond these studies, support for an environmental hypothesis also 
comes in the form of anecdotal reports of the worsening of autistic symptoms following 
gastrointestinal abnormalities (Horvath et al., 1999) and/or treatment with antibiotics 
(Finegold, Song, & Liu, 2002; Fallon, 2005). Similarly, ingestion of certain wheat or 
dairy products has also been shown to exacerbate symptoms. A subset of autistic patients 
has shown improvements in the occurrence and severity of symptoms once these dietary 
components have been removed from their diet (Jyonouchi, Sun, & Itokazu, 2002).
i
Finally, Herbert and colleagues (2006) reported the involvement of several 
environmentally responsive genes found in linkage regions that had previously been 
implicated in ASD. '
There are many comorbidities that accompany the characteristic behavioural features 
of autism. Several of these, including epilepsy, sleep disturbances, and anxiety disorders 
(Herbert et al., 2006), involve the central nervous system. Some comorbidities, such as 
recurrent infection and gastrointestinal and immune difficulties involve other systems, . 
suggesting multisystem involvement in the disorder (Herbert et al., 2006).
Substantial intra-individual variability has been noted in autistic individuals, both in 
the nature and severity of the featured symptoms. This variability can occur in the short,
23
medium, or long term, and may point to a metabolic and/or environmental factor, which is 
labile in nature (Herbert et al., 2006). Although it is common for a child’s autistic 
symptoms to wane over time, either in a spontaneous manner or in response to treatment, 
these improvements have been poorly studied until very recently (Dawson & Zanolli,
2003; Fein et al., 2005; Mundy & Crowson, 1997). This response to treatment and 
subsequent improvement implicates the action of environmentally responsive disease 
mechanisms -  the same mechanisms that could be involved in the worsening of symptoms 
as well. Herbert and her colleagues (2006) conducted a bioinformatic analysis of a set of 
environmentally responsive genes from three relevant genomic databases, all of which 
overlapped with autism linkage regions previously established in autistic patients; The 
genes studied were those involved with many different functions, including cell signaling,
homeostasis, metabolism, immune/inflammatory response, and oxidative
\
stress/metabolism (Herbert et al., 2006). From this, it was concluded that autism should 
be viewed etiologically as a systemic disorder that is influenced by both genetics and
. : v. . ■ •
environmental factors.
Based on the whole-body nature of ASD, as well as the putative involvement of a 
variety of different environmental factors, it was necessary to develop a model to study the 
processes and mechanisms involved in the disorder. Recently, the administration of 
propionic acid (PPA), as well as other short-chain fatty acids (SCFAs) has been proposed 
as a novel model for ASD in the rat (MacFabe et al., 2007; MacFabe et al., 2008; MacFabe 
et al., 2011; Shultz et al., 2008; Shultz et al., 2009; Thomas et al., 2010). PPA is a short- 
chain fatty acid that is an important metabolic fermentation product of enteric gut bacteria 
(i.e. Clostridia, Desulfovibrio, and propionibacteria) (Finegold et al., 2002; Finegold et
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al., 2010). PPA is also included in many refined wheat and dairy products as a 
preservative (Brock & Buckel, 2004). Being a weak organic acid, PPA exists in both 
water-soluble and lipophilic forms in the body and can readily cross lipid bilayers (such as 
the gut-blood and blood-brain barriers), gaining entry into systemic and/or CNS 
environments. This can occur either actively, via monocarboxylate transporters, or 
passively, through diffusion (Niederman, Zhang, & Kashket, 1997; Maurer, Canis, 
Kuschinsky, & Duelli, 2004).
PPA and other enteric SCFAs have been proposed as potential links between the 
disparate behavioural, gut, metabolic, and immune factors implicated in autism. PPA is 
known to have many physiological effects, acting on processes such as cell signaling 
(Nakao, Moriya, Furuyama, Niederman, & Sugiy, 1998), neurotransmitter synthesis and
release (DeCastro, et al., 2005), immune function (Le Poul et al., 2003), modulation of
\
gene expression (Suzuki, Nagao, Tokunaga, Katayama, & Uyeda, 1996), mitochondrial 
function (Wagner, Bayir, Ren, Puccio, Zafonte, & Kochanek, 2004), lipid metabolism
(Hara, Haga, Aoyama, & Kiriyama, 1999), and gating of gap junctions (Rorig, Klausa, &
\
Sutor, 1996), all o f which have been implicated in ASD (MacFabe et al., 2007). Beyond 
this wide array o f physiological effects of PPA, further evidence for the role of SCFAs in 
the pathogenesis of autism comes from the increased prevalence of PPA-producing 
bacterial species in the intestinal tracts of autistic patients compared to healthy controls 
(Finegold et al., 2002). Finally, altered PPA metabolism is present in many disorders, 
such as organic acidemias, camitine/B12/biotin deficiency, and exposure to valproate or 
ethanol (pre- or postnatally), all of which present with ASD-like characteristics such as
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developmental delay, GI difficulties, and seizure disorder (Coulter, 1991; Calabrese & 
Rizza, 1999; Wajner, Latini, Wyse, & Dutra-Filho, 2004).
Findings using the PPA rodent model of autism have included behavioural, 
neuropathological, biochemical, and electrophysiological characteristics, all of which are 
consistent with those seen in ASD (MacFabe et al., 2007; MacFabe et al., 2008; MacFabe - 
et al., 2011; Shultz et al., 2008; Shultz et al., 2009; Thomas et al., 2010). Behaviourally, 
traits such as bouts of hyperactivity, social impairments, perseveration, and object 
preference have been observed. Electrophysiological findings have shown both caudate 
spiking and limbic kindled seizures (MacFabe et al., 2007). Upon examination of 
neuropathological data obtained using this model, a clear innate neuroinflammatory 
response, as well as an increase in oxidative stress markers and a reduction in glutathione,
■. I ■ .
were seen in the brains o f these rats (MacFabe et al., 2007; MacFabe et al., 2008), which
\
have also been noted in autopsy data from human patients with ASD (Chauhan &
Chauhan, 2006; Vargas et al., 2005).
In 2009, Shultz and colleagues investigated the effects of brief
\
intracerebroventricular (ICV) infusions of PPA on the cognitive and sensorimotor 
functioning of Long-Evans rats, using the Morris water maze. Animals were given either 
three or five ICV infusions and then tested in the water maze for acquisition, and then 
again a week later in a maze reversal task. What was found was a highly unusual pattern 
of water maze performance, wherein rats treated with PPA were able to learn the maze 
during acquisition just as well as controls, but were unable to learn the maze reversal task 
(i.e., learn a new location of the hidden platform) due to perseveration in returning to the 
original quadrant where the platform was initially located (Shultz et al., 2009). This
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perseverative pattern o f activity is consistent with the ritualistic and repetitive behaviours 
seen in autism (Sasson, Turner-Brown, Holtzclaw, Lam, & Bodfish, 2008). This finding 
was corroborated by the fact that MacFabe and colleagues (2007) found increased 
immunoreactivity o f the activated form of cyclic AMP responsive binding protein (CREB) 
in the tissue of the hippocampus and adjacent white matter. CREB and pCREB (the 
phosphorylated and activated form) are involved in the alterations of gene expression that 
are thought to be important in learning and memory (Carlezon, Duman, & Nestler, 2005; 
Silva, Kogan, Frankland, Kida, 1998). The current study further investigated this 
phenomenon of perseveratory behaviour in the PPA rodent model.
There has been evidence of improvement in autistic symptoms following certain 
treatments, some of which involve eradication of ASD-associated bacteria, often through
treatment with antibiotics, which decrease populations of PPA-producing bacteria
\
(Finegold et al., 2002). Based on this, it was important to explore the long-term effects of 
PPA on cognition using the rodent model. Shultz et al. (2009) found that animals treated 
with single infusions of PPA had no difficulty acquiring the maze but could not, when 
given another infusion of PPA before reversal training, learn a new location of the hidden 
platform. Thus, it was important to investigate the effects of previous PPA loading after a 
brief recovery period, where no PPA was administered, on the animals’ ability to succeed 
in water maze training.
A 7-day infusion schedule, with two infusions per day, was used in the current 
study, in order to be consistent with the previous work done using the PPA rodent model
i
of autism (MacFabe et al., 2008). The present study thus differed from the previous study(
by Shultz et al. (2009), where animals were given either three or five infusions over the
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course of the experiment. The 7-day infusion schedule allowed data from the present 
studies to be compared to previous neuropathological and biochemical findings in this 
model (Thomas et al., 2010). In the present study, animals were allowed a 7-day period of 
recovery (where no infusions were administered) following the 7-day infusion schedule. It 
was hypothesized that while certain aspects of behaviour and cognition would persist even 
after PP A treatment had been stopped, many of the behavioural effects caused by PPA 
administration would return to baseline after a brief period of recovery.
2.2 Methods
2.2.1 Subjects
Subjects were 41 adult male Long-Evans hooded rats obtained from Charles River
Laboratories (Quebec, Canada) and weighed between 200 and 250 g. Rats were housed in
\
pairs in standard acrylic cages (26 cm x 48 cm x 21 cm) in a temperature controlled colony 
room (21 + 1.0 °C), and were naive to all experimental procedures. After surgery, rats 
were housed individually and allowed to recover for 7-14 days, with no treatment taking 
place during this time. The light/dark schedule was a 12:12 cycle with lights on at 07:00 h 
and animals were allowed access to food (Prolab rat chow) and water ad libitum. All test 
procedures and experimentation were carried out in accordance with guidelines of the 
Canadian Council on Animal Care (CCAC) and approved by the University of Western 
Ontario Animal Use Committee.
2.2.2 Surgery: Cannula Implantation
Animals were implanted with a 23 gauge intraventricular guide cannula using 
standard stereotaxic techniques. Rats were anaesthetized using inhaled 5% isoflurane and
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2 L/min oxygen flow. While in the stereotaxic device, rats were equipped with a gas 
anaesthesia nose cover to maintain anaesthetic throughout surgery with 3% isoflurane and 
500 mL/min oxygen flow. Under aseptic conditions, rats were implanted with a guide . 
cannula in the right lateral ventricle, with the tip of the guide cannula at the following 
coordinates with reference to Bregma: anterior/posterior -1.4 mm; medial/lateral 1.8 mm; 
dorsal/ventral -3.0 mm (Paxinos & Watson, 1986). Four small, stainless steel screws were 
inserted into the skull surrounding the cannula to provide anchors for dental acrylic, which 
attached the cannula to the skulk The cannula was sealed with a removable plug until the 
time of infusion. Immediately post-surgery, all rats received a subcutaneous injection of 
Ketoprofin (l mL/kg) as an analgesic.
2.2.3 Treatment Groups:
Rats were intracerebroventricularly infused with either phosphate buffered saline 
(PBS; 4 uL o f 0.1 M solution) or propionic acid (PPA; 4 uL of 0.26 M solution).
i
Propionic acid was buffered to a physiological pH of 7.4 using hydrochloric acid or
! ' ' ■
■ ; ■
sodium hydroxide. Treatment was divided into two phases: Phased and Phase II, to yield 
4 treatment groups. The rats receiving PBS during Phase I followed by PBS during Phase 
II were labeled PBS-PBS (n = 7). Rats receiving PPA during Phase I and PPA during 
Phase II were labeled PPA-PPA (n = 12). Rats in the PPA-PBS group received PPA 
during Phase I and PBS during Phase II (n = 13), and vice versa for rats in the PBS-PPA 
group (n = 9). During Phased, animals received two infusions of their assigned substance 
per day, at 09:00 h and 13:00 h, for seven days. For one week after these 14 infusions, the 
rats were allowed a period of rest, where no treatment took place.
■ '> '
On the day following the rest period, Phase II, rats were given two more infusions of 
either the same compound that they received during Phase !  (PBS-PBS and PPA-PPA 
groups), or o f the compound they did not receive during Phase I (PPA-PBS and PBS-PPA 
groups). Doses were chosen based on previous dose-response findings from earlier 
studies done in our lab (MacFabe et al., 2007; Shultz et al., 2008).
2.2.4 ICV Infusions
Each rat received infusions of its assigned compound directly into the right lateral 
ventricle via a 30-gauge injection cannula connected to a Sage syringe pump by PE10 
tubing. The tip of the injection cannula protruded 0.5 mm beyond the tip of the guide 
cannula. Each infusion consisted of 4 uL of solution delivered over a period of 1 min. To 
ensure that the entire infusion had been delivered, the injection cannula was allowed to
remain in place for an additional minute before being removed. On behavioural testing
\
days, infusions were given approximately 3-5 minutes prior to the test session.
2.2.5 Behavioural Test Apparatus
2.2.5.1 Open Field Apparatus. Locomotor activity was monitored in an 
EthoVisioh circular open-field arena (90 cm diameter, 40 cm high) with Beta Chip 
bedding covering the floor of the arena. A CD camera and a darkroom lamp were 
mounted above the centre of the arena. The camera was connected to a computer, 
allowing behaviour to be recorded using the EthoVision 3.0.15 Behavioral Monitoring and 
Analysis System at a rate of 5.994 frames/s. This program is capable of tracking the x-y 
coordinates of each animal and it allows for the computation of several quantitative 
variables. The camera was also connected to a VCR, allowing behaviour to be recorded 




2.2.5.2 Water Maze. Spatial cognition was assessed using a water maze consisting 
of a circular pool (1.5 m in diameter, 45 cm deep) filled with tap water at 29 ± 1.0 °C. 
Hidden approximately 2 cm below the water surface was an escape platform (9 cm x 9 
cm). The platform was located in the centre o f the south-east quadrant during acquisition 
(Phase I), and in the centre o f the north-west quadrant during reversal (Phase II). 
Polypropylene pellets floating on top of the water prevented the rats from seeing the 
hidden platform by making the surface opaque (Cain, Hargreaves, Boon, & Dennison, 
1993). Pictures and objects around the room provided a variety o f distal cues. Behaviour 
was recorded by a video camera mounted to the ceiling above the pool. The camera was 
connected to a computer and behaviour was objectively analyzed by an automated 




2. 2.6.1 Phase I. During Phase I, rats received infusions of their assigned drug twice 
a day for 7 days. On the final day of infusions, day 7, the rats were tested in the open field
v
apparatus in the morning, following their first infusion. Each rat was placed individually 
into the open field and behavioural data were collected for 30 minutes. In the afternoon, 
following the second infusion of the day, rats were tested in the water maze. Behavioural 
testing commenced within approximately 3-5 minutes of the infusion.
Rats were given 10 training trials in the water maze. Each trial began with the rat 
being placed in the pool, adjacent to, and facing, the pool wall at one of 4 quasi-random 
start locations (north, east, south, or west), and ended when the rat stood on the hidden 




acquisition. Rats that failed to reach the hidden platform within 60 s of the 
commencement of the trial were guided to the platform by the experimenter. Rats 
remained on the platform for 15s before they were placed in a drying chamber that was 
heated from above by an infrared lamp. Due to metabolic clearance rates of the injected 
substances (approximately 30 min; Brusque et al., 1999) rats were run in squads of 4 so 
that the inter-trial interval for the 10 acquisition trials was not more than 5 min. For 
graphic presentation of water maze variables, the time to reach the platform was averaged 
for every block of two trials (e.g. Block 1 = (Trial 1 + Trial 2)12). Following acquisition 
training in the water maze, rats were given no treatment for one week.
2. 2.6.2 Phase II: Reversal Training. Phase II consisted of one day of infusions (at
v
09:00 h and 13 :00 h) and testing and occurred one week after the conclusion of Phase I.
Rats again received two infusions of either PBS or PPA, with half of the rats receiving the
\ .
infusion type (PBS or PPA) that they had not received during Phase I (i.e., PPA-PBS and 
PBS-PPA groups). Following the morning infusion, rats were once again placed in the 
open field apparatus for 30 minutes and behavioural data were collected.
After the afternoon infusion, the rats were again tested in the water maze, following 
the same procedure as on the 7th day of Phase I. However, the platform was now located 
in the north-west quadrant o f the pool rather than the south-east quadrant, where it was 
located during maze acquisition.
 ̂ l
2.2.7 Statistical Analysis o f  Behaviours
All statistical tests were calculated using SPSS 18.0 (SPSS, Inc.) for Windows.
Tests were completed using a = .05 as the criterion for significant effects.
t
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2. 2.7.1 Water Maze Search Latencies, Total Distance Traveled, Time Spent in 
Periphery, Swim Speed, Number o f  Direct and Circle Swims, and Percent First Choices to 
Initial Quadrant. Search latency was defined as the time in seconds from release until the 
rat climbed onto the hidden platform. Time spent in the periphery was calculated with the 
periphery being defined as the outer 33% of the pool. A direct swim was defined as a 
swim that remained entirely within an 18 cm wide virtual alley from the start point to the 
hidden platform without crossing over itself. A circle swim was defined as a swim that 
approximated an arc of a circle without exceeding 360 degrees or crossing over itself. 
Direct and circle swims are indicative of spatial place learning and were summed for each 
test session. :
Data were analyzed using a mixed design analysis of variance (ANOVA) with
drug treatment (PBS or PPA) as the between-subjects factor and trial (10 training trials)
' \
and test day (one or two) as the within-subjects factor. Student-Newman-Keuls (S-N-K) 
post-hoc tests were carried out to obtain group differences on individual trials. ■
■'■"2.2.7.2 Open Field Total Distance Traveled, Average Speed, and Time Spent in 
Periphery. Data were analyzed for main effects using a mixed design ANOVA with drug 
treatment (PBS or PPA) as the between-subjects factor and time bin (six 5-min time bins) 
and test day (one or two) as the within-subjects factor.
2.2.8 Monitoring o f  Convulsive Activity
Rats were closely monitored for possible convulsive behaviour. Past studies from 
our lab have found a kindling effect associated with repeated daily ICV infusions of PPA 
in some rats (MacFabe etal., 2007). The onset of seizures may be an issue in studies
investigating cognition or sensorimotor ability if a seizure were to occur prior to, or during 
testing.
2.3 Results
2.3.1 Baseline Locomotor Activity
There were no significant group differences among the drug groups for any of the 
variables measured prior to drug treatment.
2.3 2 Open Field
2.3.2.1 Total Distance Traveled. In the open field apparatus, all rats traveled 
significantly less across time, F(5,195) = 25.405, p  < .001. The PPA-treated group 
exhibited significantly greater distances traveled than PBS controls, F( 1, 39) = 19.716, p  < 
.001, as seen in Fig. 2.1a. There was no significant interaction between time and drug,
F (5 ,195) = 2.034, p  = .328.
\
On reversal day, all rats once again traveled significantly less across time in the open 
field, F(5, 185) = 13.863,/? < .001. There was no significant main effect of drug, 
however, F(3, 37) = 1.283,/? = .295 (Fig. 2.1b).
2.3.2.2 Average Speed. All rats tended to travel at a higher speed in the beginning of 
the session compared to the end, F{5,195) = 103.720,/? < .001 (Fig. 2.2a). The PPA- 
treated group exhibited significantly greater average speeds than PBS controls across all 
time bins, F{1, 39) = 19.433,/? < .001. There was no significant interaction between time
I
and drug, F(5,195) = 1.666,/? = .171.
On reversal day, all rats once again traveled at significantly lower average speeds
s'1
across time in the open field, F(5, 185) = 83.483,/? < .001 (Fig. 2.2b). There was no 




Figure 2.1 Total distance (cm) traveled in open field on Acquisition day (A) and total 
distance traveled on Reversal day (B) for rats injected (ICV) with either PBS 
(vehicle) or PPA (0.26M). Each point represents group mean data for each time bin 
in the 30 minute session immediately following injection. Error bars represent + 
SEM. PPA-treated animals traveled significantly greater distance on Acquisition 
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Figure 2.2 Average speed (cm/s) in the open field apparatus on Acquisition day (A) 
and average speed on Reversal day (B) for rats injected (ICV) with either PBS 
(vehicle) or PPA (0.26M). Each point represents group mean data for each time bin 
in the 30 minute session immediately following injection. Error bars represent + 
SEM. PPA-treated rats exhibited significantly greater average speed than PBS 
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regardless of drug treatment, F{3, 37) = .862, p  = .469.
2.3.2.3 Time Spent in Periphery. In the open field apparatus, all rats spent less time 
in the periphery of the arena across time, F(5, 185) = 11.891 ,P <  .001. However, there 
was no significant main effect of drug, F(1, 37) = 2.668, p  = . 111. There was also no 
significant interaction between time and drug, F(5,185) = 1.161 ,p  = .328 (Fig. 2.3a).
On reversal day, all rats once again spent significantly less time in the periphery of 
the open field over the course of the testing session, F(5, 185) = 19.756,/? < .001 (Fig. 
2.3b). There was no significant main effect of drug, F(3, 37) = .352, p  = .788.
2.3.3 Water Maze f : ' r .
2.3.3.1 Removal o f  Data from Convulsive Rats. Throughout the experiment, several 
rats experienced convulsive activity during acquisition of the water maze, which occurred
immediately following infusion. This is a common feature of rats subjected to this
\
particular infusion schedule. Because of the nature of the task, the data collected from 
these rats was excluded from water maze analyses. In total, water maze data from 16 rats 
was excluded.
2.3.3.2 Search Latencies. During acquisition training, all treatment groups exhibited 
decreased search times as training progressed. Significant main effects were found for 
both trial, F(9,207) = 11.421,/? < .001, and drug treatment FT(1,23) = 14.755,p  < .01.
j
There was also found to be a significant interaction between trial and treatment, F (9 ,207) 
= 3.536, p  < .01, indicating that PPA-treated rats exhibited longer search latencies on 
blocks 2, 3 ,4 , and 5 (Fig. 2.4a).
On reversal Day, as shown in Fig. 2.4b, all treatment groups exhibited decreased 
search times as training progressed, F(9, 189) = 8.084, p  < .001. However, there were no
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Figure 2.3 Time (s) spent in the periphery of the open field on Acquisition day (A) 
and on Reversal day (B) for rats injected (ICV) with either PBS (vehicle) or PPA 
(0.26M). Each point represents group mean data for each time bin in the 30 minute 
session immediately following injection. Error bars represent + SEM. There were 
no differences on either test day in the amount of time spent in the periphery of the 
open field.
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Figure 2.4 Search latencies (s) to find the hidden platform on Acquisition day (A) 
and on Reversal day (B) for rats injected with either PBS (vehicle) or PPA (0.26M). 
Each point represents group mean data for each of 10 trials immediately following 
injection. Error bars represent + SEM. * p < .05. Search latencies of PPA-treated 
rats improved less across the 10 trials than controls on Acquisition day, and there 
was also found to be a significant interaction between trial and drug treatment, with 
search latencies of PPA rats being significantly higher than those of PBS rats on 
trial blocks 2 through 5. On reversal day, there were no significant group 
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significant differences found among groups on reversal day F(3, 21) = 2.421, p  = .061. 
There was also found to be no significant interaction between trial and treatment, F(27, 
189) = .703, p  = .686, indicating that the improvement across trials was similar across 
drug groups.
2.3.3.3 Total Distance Traveled. During acquisition training, all treatment groups 
exhibited decreased distances traveled as training progressed, as seen in Fig 2.5a. 
However, distances traveled by PPA-treated rats decreased less than the PBS controls. 
These impressions were confirmed by ANOVA, with significant main effects being found 
for both trial, F(9, 189)= 10.143, p <  .001, and drug treatment F (\, 21) = 19.212, /?< 
.001. There was also found to be a significant interaction between trial and drug 
treatment, F (9 ,189) = 3.971,/? < .01, indicating that the decrease in total distance traveled
across trials was greater in the PBS group than in the PPA group. PPA-treated rats
\
continued to travel larger distances compared to controls on trial blocks 2 through 5.
On reversal Day, as shown in Fig 2.5b, all treatment groups exhibited decreased
distances traveled across trials, F(9, 189) = 6.239,/? < .001. However, groups receiving
' \ ' 
PPA on reversal day continued to travel larger distances than controls, F (3 ,21) = 4.230,/?
< .05. There was no significant interaction between trial and drug treatment, F(27,189) =
.800,/? = .276, indicating that the improvement across trials was similar across drug
groups.
•i
2.3.3.4 Time Spent in the Periphery o f  the Pool. During acquisition training, all 
treatment groups exhibited decreased time spent in the periphery of the pool as training
44
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Figure 2.5 Total distance (cm) traveled in the water maze on Acquisition day (A) 
and on Reversal day (B) for rats injected with either PBS (vehicle) or PPA (0.26M) 
Each point represents group mean data for each of 10 trials immediately following 
injection. Error bars represent + SEM. * p < .05. PPA-treated rats traveled 
significantly greater distances on Acquisition day. There was a significant 
interaction between trial and drug treatment, with PPA-treated rats continuing to 
travel significantly larger distances across trial blocks 2 through 5 than PBS rats. 
On Reversal day, there was a main effect of drug treatment.
\
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progressed (Fig 2.6a). However, PPA-treated rats continued to spend more time in the 
periphery than the PBS controls. These impressions were confirmed by ANOVA, with 
significant main effects being found for both trial, F(9,189) = 13.793,/? < .001, and drug 
treatment F (l, 21) = 10.664,/? < .01. There was also a significant interaction between 
trial and drug treatment, F(9,189) = 3.949, p  < .01, indicating that the decrease in time 
spent in the periphery o f the pool across trials was less for the PPA-treated rats than for 
controls. PPA rats continued to spend more time in the periphery over trial blocks 2, 3,4, 
and 5.
On reversal Day, as seen in Fig 2.6b, all treatment groups exhibited decreased time 
spent in the periphery o f the pool across trials, F(9,189) = 7.916, < .001. There was 
also a significant main effect of drug F (3 ,21) = 4.075,/? < .05. There was found to be no 
significant interaction between trial and treatment, F(27,189) = .884, p -  .340, indicating 
that the improvement across trials was similar across drug groups. ,
• : V ’ ,
2.3.3.6 Number o f  Direct and Circle Swims. As shown in Fig. 2.7a, during
acquisition training the PPA-treated group exhibited fewer direct and circle swim paths
\
than PBS controls. ANOVA confirmed this impression, revealing a significant treatment
■ (
effect, F{1, 21) = 12.588, p  < .01, with the PPA group displaying fewer direct and circle 
swims than PBS controls.
As shown in Fig 2.7b, during reversal training there was no significant main effect 
of treatment, F (3 ,18) = 3.028,/? = .056.
2.4 Discussion
This study examined the lasting cognitive effects of ICV PPA loading, after a 
one-week recovery period. It was found that treatment with PPA twice a day for seven
47
Figure 2.6 Time spent in the periphery (s) of the water maze on Acquisition day (A) 
and on Reversal day (B) for rats injected with either PBS (vehicle) or PPA (0.26M). 
Each point represents group mean data for each of 10 trials immediately following 
injection. Error bars represent + SEM. * p < .05. The periphery represents the 
outer third of the pool. On Acquisition day, PPA-treated rats spent more time in the 
periphery than controls on trial blocks 2, 3, 4, and 5. On Reversal day, there was a 
significant main effect of drug.
48
Time Spent in Periphery of Water Maze on Acquisition Day
Time Spent in Periphery of Water Maze on Reversal Day
Block
49
Figure 2.7 Number of direct and circle swims on Acquisition day (A) and on 
Reversal day (B) for rats injected with either PBS (vehicle) or PPA (0.26M). Each 
bar represents group mean data immediately following injection. Error bars 
represent + SEM. * p < .05. Rats treated with PPA exhibited significantly fewer 
direct and circle swims than controls. On reversal day, there were no significant 
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consecutive days caused impairments in water maze acquisition. This was observed 
through longer search latencies, increases in travel distances, and fewer direct and circle 
swims.
2.4.1 Water Maze
The variables analyzed in the water maze were search latency, total distance 
traveled, time spent in the periphery, swim speed, number of direct and circle swims, and 
percent first choices to initial quadrant. On both test days, it was observed that animals 
were able to learn the water maze, with performance on all variables improving across 
trials. However, animals given PPA improved less across trials than did controls. 
Significant group differences were seen on all variables except for swim speed on 
acquisition and reversal days (data not shown), and percent first choices to initial quadrant
during reversal (F(3, 18) = .376, ns). The lack of a significant group difference in swim
\
speed suggests that there were no major motor impairments experienced by the PPA- 
treated rats: The finding that PPA-treated rats exhibited the same percentage of first 
choices to the initial platform-containing quadrant on reversal day suggests that PPA- 
treated rats in the present study did not show perseverative behaviour as was found in the 
study by Shultz et al. (2009), where animals received single, spaced infusions of the 
compound. This could be due to the fact that animals given PPA during Phase I were 
impaired in acquiring the maze to begin with, and thus had no initial memory of the 
location of the platform on which to perseverate.
Rats who received PPA for seven days prior to water maze acquisition were 
impaired in the maze. They were unable to learn the maze as well as controls, and this 
was seen in increased search latencies, larger total travel distances, more time spent in the
52
periphery of the pool, and fewer direct and circle swims. All of these findings point 
towards impairments in the learning of adaptive behavioural strategies in the maze. This 
finding is inconsistent with what was observed by Shultz et al. (2009), where animals 
administered PPA showed a pattern of learning that was statistically no different than 
controls during water maze acquisition. Shultz and colleagues (2009) found that PPA- 
treated rats displayed a pattern of water maze activity that was the opposite of what is 
typically seen. Rats were not impaired in acquiring the maze, but showed a marked 
impairment during maze reversal. This difference in findings is likely explained by the 
difference in methods between the present study and the study by Shultz et al (2009). In ;
j
the previous study, rats were given either three or five single (i.e., one infusion per day) 
ICV infusions of PPA over the course of a week prior to water maze training. In the
present study, rats were tested for maze acquisition following 14 infusions of PPA
\ ■
administered over seven consecutive days. It has been shown that infusions of PPA can 
have cumulative effects in rodents! MacFabe et al. (2007) found that five consecutive days 
of single PPA infusions lead to a progressive increase in the maximum level of convulsive
' v
stage measured, as well as an increased response to a pentylenetetrazol (PTZ) treatment, 
which lead to the conclusion that repeated, spaced infusions of PPA have a kindling effect 
in rodents. Similarly, occurrences of abnormal behaviours such as limb dystonia and 
hyperactivity have been shown to increase in frequency, as well as an increase in 
neuroinflammation, with number of spaced infusions (MacFabe et al., 2007; MacFabe et 
al., 2008). Based on this, it is likely that PPA loading has a number of cumulative effects, 
both physiologically and cognitively, that need to be explored further.
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. Shultz et al. (2009) concluded based on their findings that rats given either three or 
five single infusions of PPA showed perseveration of behaviour in the water maze, which 
was consistent with what is seen in the human disorder (Sasson et al., 2008), as well as 
further findings from our lab (MacFabe et al., 2011). The marked impairment observed in 
these rats during reversal training, accompanied by the increased percentage of first 
choices to the quadrant where the platform was initially located during acquisition, suggest 
that the animals were having difficulty unlearning the maze. This type of perseverative 
behaviour was not observed in the present study, with PPA animals showing no preference 
for the south-east quadrant during reversal (data not shown). Instead, what was observed 
was a general deficit in water maze performance.
2.4.2 Recovery to Baseline
The purpose o f this study was to examine whether or not the observed cognitive
\
deficits caused by PPA would return to baseline after administration of the compound had 
been discontinued for a substantial period of time. Due to the fluctuating course of ASD 
symptomatology, researchers are beginning to look into the idea of “recovery” in autism; a 
concept that is not yet clearly defined. Helt and colleagues (2008) suggest that recovery 
should be looked at as the loss of the behavioural characteristics of ASD, bearing in mind 
that these children are often still not identified as “normal”. To be considered 
“recovered”, a term that is used conservatively in research, a child who had previously 
been diagnosed with ASD must now be learning and applying new skills which are at an 
appropriate age and developmental level for that child (Helt et al., 2008). For the purposes 
of this study, it could be said that to be considered as “recovered”, a return to baseline 
should be achieved on all variables measured, i.e., the animal is able to reverse the maze
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once drug administration has been discontinued. The findings of the present study suggest 
that recovery to baseline after previous PPA loading (i.e., two infusions per day for seven 
days) appears possible, based on the behaviours tested in the water maze and open field, 
following discontinuation o f the drug for a period of seven days. Animals who received 
two final infusions of PPA on reversal day, regardless of which drug they received during 
Phase I of the study, were impaired in reversing the maze compared to controls, 
suggesting that two infusions of PPA are enough to cause deficits in cognition. Animals 
in the PPA-PBS group (i.e., the “recovery” group) showed a pattern of performance on 
reversal day that was often at the same level as controls. The “recovery” group did show 
an intermediate level of performance by traveling longer distances and spending more 
time in the periphery of the pool than controls, however this finding did not reach
significance. This suggests that certain behaviours return to baseline, whereas others may
\
be more permanent. Further research should be conducted to explore whether or not these 
intermediate deficits remain over a longer time period, or whether performance of 
previously PPA-loaded animals can return completely to baseline if  given sufficient time 
to recover. Similarly, it would be beneficial to investigate the time course of other 
behaviours that are relevant to ASD (i.e., social behaviours), as well as other 
neuropathological (i.e., CREB) and biochemical (i.e., phospholipid/acylcamitine) markers. 
All of these studies are ongoing in our laboratory.
There are varying levels of cognitive impairment observed in individuals with ASD. 
The disorder can occur with or without cognitive impairment, with some individuals 
experiencing profound deficits in IQ and others achieving normal levels (Dawson, 
Soulieres, Gemsbacher, & Mottron, 2007). In fact, the reported percentages of children
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with ASD who fall in the range defined as mental retardation are between about 25 and 
64% (Kielinen, Linna, & Moilanen,' 2000). The present study models a more severe 
cognitive impairment, which has been shown to be dependent on dose of PPA in our 
model (MacFabe et al., 2007). It is interesting that even though these animals experienced 
extreme cognitive impairments in the water maze, they were still able to show
improvements to baseline levels following discontinuation of PPA treatment. ,
( - ' '
2,4.3 Convulsive Activity
In the present study, water maze data from 16 of the 41 animals tested was removed
due to convulsive activity that was observed during acquisition training in the water maze.
o
Many rats experience convulsive activity as a result of continued PPA infusions. The 
kindling effect of PPA has been well noted (MacFabe, 2007), and so the presence of
convulsions throughout such a rigorous infusion schedule, such as the one used in the
v . 'i ' ■ , < •\
present study, is not surprising. Although it cannot be concluded that some or all of the 
convulsive activity seen following infusions was actually seizure activity without EEG - 
data, it is a possibility. Furthermore, some seizure types (i.e., hippocampal seizures) 
produced by PPA are conconvulsive and present with movement arrest or immobility 
(MacFabe et al., 2007). Conversely, movement disorder has been observed in the model, 
which appears as convulsive behaviour. This behaviour, however, was accompanied by 
basal ganglial spiking rather than cortical spiking, which is more often characteristic of 
seizure (MacFabe et al., 2007). If a seizure were to occur prior to or during testing, this 
would interfere with cognition and thus the animal’s ability to acquire the maze. 
Convulsive activity was also often observed as full-body clonus, which alone can make
* C
activities such as swimming and climbing onto a platform very difficult. It was for this
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reason that data from rats that displayed convulsive activity was removed entirely from all 
water maze analyses. This, however, leads to a slightly different problem, where rats that 
were resistant to convulsive/seizure activity were selected for, unintentionally. It is 
possible that the rats that were able to receive 14 infusions o f PPA over the course of 
seven days without displaying convulsive activity have some common characteristic that 
could have skewed the data presented here. Similarly, because seizure disorder is a 
common comorbidity of ASD (Besag, 2004), eliminating this data may have resulted in 
the exclusion of data that may have been informative. For the purposes of this study, 
however, the conservative choice of leaving these data out of the behavioural analyses for 
water maze was deemed more suitable. Further studies should be conducted to elucidate 
the precise role that convulsive activity plays in the model.
2.4.4 Conclusions
Findings from the present study are suggestive of a return to baseline on behavioural 
variables measured in the water maze arid open field apparatus following discontinuation 
of PPA treatment. The cognitive deficits caused by PPA did not appear to be the result of 
perseveration in the water maze, as was seen in previous work by Shultz et al. (2009). 
Instead, the animals appeared to be unable to acquire or reverse the maze immediately 
following PPA infusion. Interestingly, this severe cognitive impairment-returned to 
baseline levels after discontinuation of PPA treatment, indicating that the cognitive 
deficits measured in the water maze resulting from PPA treatment are not permanent.
2.5 References
Arndt, T. L., Stodgell, C. J., & Rodier, P. M. (2005). The teratology of autism. 
International Journal o f  Developmental Neuroscience ,23 , 189-199.
57
Ashwood, P., & Van de Water, J. (2004). Is autism an autoimmune disease? Autoimmunity 
Reviews, 3, 557-562.
Besag, F.M. (2004). The department of health action plan “improving services for people 
with epilepsy”: A significant advance or only a first step? Seizure, 13(8), 553-564.
Brock, M., & Buckel, W. (2004). On the mechanism of action o f the antifungal agent 
propionate. European Journal o f  Biochemistry, 271, 3227-3241.
Brusque, A.M., Mello, C.F., Buchanan, S.T., Terracciano, S.T., Rocha, M.P., Vargas, C.R., 
et al. (1999). Effect of chemically induced propionic acidemia on neurobehavioral 
development of rats. Pharmacology and Biochemistry o f  Behaviour, 64, 529-534.
Cain, D.P., Hargreaves, E.L., Boon, F., & Dennison, Z. (1993). And examination of the 
relations between hippocampal long-term potentiation, kindling, afterdischarge, and place 
learning in the water maze. Hippocampus, 3(2), 153-163.
Calabrese, V., & Rizza, V. (1999). Formation of propionate after short-term ethanol 
treatment and its interaction with the carnitine pool in rat. Alcohol, 1 9 ,169-176.
Carlezon, W.A., Duman, R.S., & Nestler, E.J. (2005). The many faces of CREB. Trends in 
Neuroscience, 28(8), 436-445.
Centers for Disease Control & Prevention. (2009). Prevalence of Autism Spectrum 
Disorders - Autism & Developmental Disabilities Monitoring Network. MMWR 
Surveillance Summaries, 58 (SS-10), 1-20. \
Chauhan, A., & Chauhan, V. (2006). Oxidative stress in autism. Pathophysiology, 13, 171- 
181.
Coulter, D. L. (1991). Carnitine, valproate, and toxicity. Journal o f  Child Neurology, 6, 7- 
14.
Curtis, J.T., Hood, A.N., Chen, Y., Cobb, G.R., & Wallace, D.R. (2010). Chronic metals 
ingestion by prairie voles produces sex-specific deficits in social behavior: An animal 
model of autism. Behavioural Brain Research, 213, 42-49.
Dawson, M., Soulieres, I., Gernsbacher, M.A., & Mottron, L. (2007). The level and nature 
of autistic intelligence. Psychological Science, 18, 657-662.
Dawson, G. & Zanolli, K. (2003). Early intervention and brain plasticity in autism. 
Novartis Found Symp, 251, 266-274 discussion 274-80, 281-97
DeCastro, M., Nankova, B. B., Shah, P., Patel, P., Mally, P. V., Mishra, R., et al. (2005). 
Short chain fatty acids regulate tyrosine hydroxylase gene expression through a cAMP- 
dependent signaling pathway. Brain Research Molecular Brain Research, 142, 28-38.
DiCicco-Bloom, E., Lord, C., Zwaigenbaum, L., Courchesne, E., Dager, S. R., Schmitz,
C., et al. (2006). The developmental neurobiology of autism spectrum disorder. The 
Journal o f  Neuroscience, 62, 6897-6906.
Fallon, J. (2005). Could one of the most widely prescribed antibiotics 
amoxicillin/clavulanate "augmentin'1 be a risk factor for autism? Medical Hypotheses, 64, 
312-315.
Fatemi, S. H., Cuadra, A. E., El Fakahany, E. E., Sidwell, R. W., & Thuras, P. (2000). 
Prenatal viral infection causes alterations in nNOS expression in developing mouse brains. 
Neuroreport, 1 1 ,1493-1496.
Fein , D., Dixon, P., Paul, J., & Levin, H. (2005) Pervasive developmental disorder can 
evolve into ADHD: Case illustrations. Journal o f  Autism and Developmental Disorders, 
35,525-534
Finegold, S.M., Dowd, S.E., Gontcharova, V., Liu, C., Henley, K.E., Wolcott, R.D, et al. 
(2010). Pyrosequencing study of fecal microflora of autistic and control children. 
Anaerobe, 16, 444-453.
Finegold, S. M., Song, Y .,&  Liu, C. (2002). Taxonomy-general comments and update on 
taxonomy of Clostridia and Anaerobic cocci. Anaerobe, 8 ,283-285.
Hara, H., Haga, S., Aoyama, Y., & Kiriyama, S. (1999). Short-chain fatty acids suppress 
cholesterol synthesis in rat liver and intestine. Journal o f  Nutrition, 129, 942-948.
Helt, M., Kelley, E., Kinsboume, M., Pandey, J., Boorstein, H., Herbert, M., & Fein, D. 
(2008). Can children with autism recover? If so, how? Neuropsychological Review, 18,
339-366. . . . .  r ; , ; ; ,
Herbert, M. R., Russo, J. P., Yang, S., Roohi, J., Blaxill, M., Kahler, S. G., et al. (2006). 
Autism and environmental genomics. Neurotoxicology , 27, 671-684.
Horvath, K., Papadimitriou, J. C., Rabsztyn, A., Drachenberg, C., & Tildon, J. T. (1999). 
Gastrointestinal abnormalities in children with autistic disorder. Journal o f  Pediatrics,
135,559-563. . . . . ,,, _ :v
Horvath, K., & Perman, J. A. (2002). Autism and gastrointestinal symptoms. Current 
Gastroenterology Reports , 4 (3), 251-258.
Hu, V. W., Frank, B. C., Heine, S., Lee, N. H., & Quackenbush, J. (2006). Gene 
expression profiling o f lymphoblastoid cell lines from monozygotic twins discordant in 
severity of autism reveals differential regulation of neurologically relevant genes. BMC 
Genomics, 7, 118.
Ingram, J. L., Peckham, S. M., Tisdale, B., & Rodier, P. M. (2000). Prenatal exposure of 
rats to valproic acid reproduces the cerebellar anomalies associated with autism. 
Neurotoxicology and Teratology , 22, 319-324. - ;
Jyonouchi, H., Sun, S., & Itokazu, N. (2002). Innate immunity associated with 
inflammatory responses and cytokine production against common dietary proteins in 
patients with autism spectrum disorder. Neuropsychobiology, 46, 76-84.
5 8
59
Kielinen, M., Linna, S.L., & Moilanen, I. (2000). Autism in Northern Finland. European 
Child and Adolescent Psychiatry, 9, 162-167.
King, M., & Bearman, P. (2009). Diagnostic change and the increased prevalence of 
autism. International Journal o f  Epidemiology, 38 (5),1224-1234.
Le Poul, E., Loison, C., Struyf, S.E., Springael, J.Y., Lannoy, V., Decobecq, M.E, et al. 
(2003). Functionaly characterization o f human receptors for short chain fatty acids and 
their role in polymorphonuclear cell activation. The Journal o f  Biological Chemistry, 278, 
25481-25489.
MacFabe, D.F., Cain, N.E., Boon, F., Ossenkopp, K.-P., & Cain, D.P. (2010). Effects of 
the enteric bacterial metabolic product propionic acid on object-directed behavior, social 
behavior, cognition, and neuroinflammation in adolescent rats: Relevance to autism 
spectrum disorder. Behavioural Brain Research, 217, 47-54.
MacFabe, D., Cain, D., Rodriguez-Capote, K., Franklin, A., Hoffman, J., Boon, F., et al. 
(2007). Neurobiological effects o f intraventicular propionic acid in rats: Possible role of 
short chain fatty acids on the pathogenesis and characteristics of autism spectrum 
disorders. Behavioural Brain Research ,176, 149-169.
MacFabe, D., Rodriguez-Capote, K., Hoffman, J., Franklin, A., Mohammad-Asef, Y., 
Taylor, R., et al. (2008). A novel rodent model of autism: intraventricular infusions of 
propionic acid increase locomotor activity and induce neuroinflammation and oxidative 
stress in discrete regions of adult rat brain. American Journal o f  Biochemistry and 
Biotechnology, 4 (2), 146-166. x
Maurer, M. H., Canis, M., Kuschinsky, W., & Duelli, R. (2004). Correlation between local 
monocarboxylate transporter 1 (MCT1) and glucose transporter 1 (GLUT 1) densities in 
the adult rat brain. Neuroscience Letters, 355, 105-108.
Mundy, P., & Crowson, M. (1997). Joint attention and early social communication: 
Implications for research on intervention with autism. Journal o f  Autism and 
Developmental Disorders, 27(6), 653-676.
Narita, N., Kato, M., Tazoe, M., Miyazaki, K., Narita, M., & Okado, N. (2002). Increased 
monoamine concentration in the brain and blood of fetal thalidomide- and valproic acid- 
exposed rat: putative animal models for autism.Pediatric Research, 52, 576-579.
Nakao, S., Moriya, Y., Furuyama, S., Niederman, R., & Sugiy, H. (1998). Propionic acid 
stimulates superoxide generation in human neutrophils. Cell Biology International, 22, 
331-337.
Newschaffer, C. J., Falb, M. D., & Gurney, J. G. (2005). National autism prevalence 
trends from United States special education data. Pediatrics, 115 (3), e277-282.
Niederman, R., Zhang, J., & Kashket, S. (1997). Short-chain carboxylic-acid-stimulated, 
PMN-mediated gingival inflammation. Critical Reviews in Oral Biology & Medicine, 8, 
269-290.
60
Patterson, P.H. (2009). Immune involvement in schizophrenia and autism: Etiology, 
pathology and animal models. Behavioural Brain Research, 204(2), 313-321.
Rorig, B., Klausa, G., & Sutor, B. (1996). Intracellular acidification reduced gap junction 
coupling between immature rat neocortical pyramidal neurons. Journal o f  Physiology,
490 (pt-1), 31-49.
Rutter, M. (2005). Incidence o f autism spectrum disorders: changes over time and their 
meaning. Acta Paediatrica, 94 (1), 2-15.
Sasson, N.J., Turner-Brown, L.M., Holtzclaw, T.N., Lam, K.S., & Bodfish, J.W. (2008). 
Children with autism demonstrate circumscribed attention during passive viewing of 
complex social and nonsocial picture arrays. Autism Research, 1, 31-42.
Shultz, S. R., MacFabe, D. F., Ossenkopp, K.-P., Scratch, S., Whelan, J., Taylor, R., et al. 
(2008). Intracerebroventricular injection of propionic acid, an enteric bacterial metabolic 
end-product, impairs social behaviour in the rat: Implications for an animal model of 
autism. Neuropharmacology, 54, 901-911.
Shultz, S. R., MacFabe, D. K., Martin, S., Jackson, J., Taylor, R., Boon, F., et al. (2009). 
Intracerebroventricular injections of the enteric bacterial metabolic product propionic acid 
impair cognition and sensorimotor ability in the Long-Evans rat: further development of a 
rodent model of autism. Behavioral Brain Research, 200, 33-41.
Silva, A.J., Kogan, J.H., Frankland, P.W., Kida, S. (1998). CREB and memory. Annual 
Reviews in Neuroscience, 2 1 ,127-148. '
Suzuki, K., Nagao, K., Tokunaga, J., Katayama, N., & Uyeda, M. (1996). Inhibition of 
DNA methyltransferase by microbial inhibitors and fatty acids. Journal o f  Enzyme 
Inhibition, 70,271-280.
Thomas, R. H., Foley, K. A., Mepham, J. R., Tichenoff, L. J., Possmayer, F., & MacFabe, 
D. F. (2010). Altered brain phospholipid and acylcarnitine profiles in propionic acid 
infused rodents: further development of a potential model of autism spectrum disorders. 
Journal o f  Neurochemistry, 113 (2), 515-529.
Vargas, D. L., Nascimbene, C., Krishnan, C., Zimmerman, A. W., & Pardo, C. A. (2005). 
Neuroglial activation and neuroinflammation in the brain of patients with autism. Annals 
o f  Neurology, 57, 67-81.
Wagner, A, K., Bayir, H., Ren, D., Puccio, A., Zafonte, R. D., & Kochanek, P. M. (2004). 
Relationships between cerebrospinal fluid markers of excitotoxicity, ischemia, and 
oxidative damage after severe TBI: the impact of gender, age, and hypothermia. Journal o f  
Neurotrauma, 27,125-136.
Wajner, M., Santos, K. D., Schlottfeldt, J. L., Rocha, M. P., & Wannmacher, C. M.
(1999). Inhibition of mitogen-activated proliferation of human peripheral lymphocytes in 
vitro by propionic acid. Clinical Science, 96, 99-103.
61
Chapter 3:
Acid-Treated Rats With and Without a Recovery Period
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3.1 Introduction
Autism spectrum disorders (ASDs) are a cluster of neurodevelopmental disorders 
that generally present with communication deficits, social impairments, motor 
abnormalities, and restricted or ritualistic interests (Arndt, Stodgell, & Rodier, 2005; 
DiCicco-Bloom et al., 2006). Environmental factors are being considered more widely in 
autism research as potential contributors to the development and/or exacerbation of ASD 
(Ashwood & Van de Water, 2004; Chauhan & Chauhan, 2006; Herbert et ah, 2006; 
Horvath & Perman, 2002). The increasing prevalence of the disorder (Centers for Disease 
Control & Prevention, 2009), as well as the lack of complete concordance between 
monozygotic twins (Hu, Frank, Lee, & Quackenbush, 2006), have lead researchers to 
investigate potential environmental agents that may contribute to the disorder. For 
instance, studies have investigated the effects of pre- and postnatal exposure to valproic 
acid (Ingram, Peckham, Tisdale, & Rodier, 2000), ethanol (Arndt, Stodgell, & Rodier, 
2005), and thalidomide (Narita, Kato, Tazoe, Miyazaki, Narita, & Okado, 2002).
Similarly, exposure to certain metals and viral infections has been implicated as well 
(Curtis, Hood, Chen, Cobb, & Wallace, 2010; Fatemi, Cuadra, El Fakahany, Sidwell, & 
Thuras, 2000; Patterson, 2009). ASD is beginning to be considered as a multisystem 
disorder involving immune, digestive, and metabolic dysfunction, all of which can be 
triggered by these environmental factors in genetically susceptible individuals (Ashwood 
& Van de Water, 2004; Chauhan & Chauhan, 2006; Herbert et ah, 2006; Horvath & 
Perman, 2002).
Further support for an environmental hypothesis comes from anecdotal reports of 
parents of autistic children of the worsening of autistic symptoms following
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gastrointestinal abnormalities (Horvath, Papadimitriou, Rabsztyn, Drachenberg, & Tildon, 
1999) and routine or antibiotic-resistant pediatric infections (Finegold, Song, & Liu, 2002; 
Fallon, 2005). Similarly, it has been reported that the worsening of symptoms can follow 
the ingestion of wheat or dairy products in a subset of patients. Some patients also show 
improvement in ASD symptoms following the removal of these types of foods from the 
diet (Jyonouchi, Sun, & Itokazu, 2002). Based on these findings, Herbert et al. (2006) 
investigated the possibility of “environmentally responsive genes” that may be associated 
with ASD symptomatology. What they found was the presence of several 
environmentally responsive genes that had previously been identified in linkage regions 
associated with ASD. Among the genes studied by Herbert and her colleagues (2006) 
were those involved with many different functions, including cell signaling, homeostasis, 
metabolism, immune/inflammatory response, and oxidative stress/metabolism. This 
finding points towards autism being a whole-body, systemic disorder rather than just a 
brain disorder, whose development and symptomatic presentation are influenced by both 
genetics and environmental factors.
Research is beginning to show that autistic symptoms in certain individuals can wax 
and wane depending on various factors such as diet or treatment with antibiotics or 
antioxidants (Horvath, Papadimitriou, Rabsztyn, Drachenberg, & Tildon, 1999). In fact, 
the intra-individual variability in the nature and severity of symptoms that has been 
reported is substantial (Herbert et al., 2006). This response to treatment and/or potential 
spontaneous improvement, which has been shown to happen in the short, medium, or long 
term, points towards the action of environmentally responsive disease mechanisms. These 
same mechanisms could also be involved in the observed worsening of symptoms. This
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empirical evidence of improvement and/or worsening of autistic symptoms suggests that 
the idea of “recovery” is an area that should be further explored.
Based on the implication of an environmental contribution to ASD, the propionic 
acid (PPA) model of autism has been proposed (MacFabe et al., 2007; MacFabe et al., 
2008; MacFabe, Cain, Boon, Ossenkopp, & Cain, 2011; Shultz et al., 2008; Shultz et al., 
2009; Thomas, Foley, Mepham, Tichenoff, Possmayer, & MacFabe, 2010). PPA is a 
short-chain fatty acid that is an important metabolic byproduct of fermentation of certain 
types of bacterial species in the gut (i.e., Clostridia, Desulfovibrio, and propionibacteria) 
(Finegold et al., 2002; Finegold et al., 2010). PPA is also included in many refined wheat 
and dairy products as a preservative (Brock & Buckel, 2004). As a weak organic acid, 
PPA exists in both water-soluble and lipophilic forms in the body and can readily cross 
lipid bilayers (such as the gut-blood and blood-brain barriers), gaining entry into systemic 
and/or CNS environments. This occurs both actively, via monocarboxylate transporters, 
and passively, through diffusion (Niederman, Zhang, & Kashket, 1997; Maurer, Canis, 
Kuschinsky, & Duelli, 2004).
PPA and other enteric SCFAs have been proposed as potential links between the 
disparate behavioural, gut, metabolic, and immune factors implicated in autism. There are 
many known physiological effects of PPA, including effects on cell signaling (Nakao, 
Moriya, Furuyama, Niederman, & Sugiy, 1998), neurotransmitter synthesis and release 
(DeCastro, et al., 2005), immune function (Le Poul et al., 2003), modulation of gene 
expression (Suzuki, Nagao, Tokunaga, Katayama, & Uyeda, 1996), mitochondrial 
function (Wagner, Bayir, Ren, Puccio, Zafonte, & Kochanek, 2004), lipid metabolism 
(Hara, Haga, Aoyama, & Kiriyama, 1999), and gating of gap junctions (Rorig, Klausa, &
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Sutor, 1996), all of which have been implicated in ASD (MacFabe et al., 2007). In 
addition to the widespread effects of PPA, further evidence for the involvement of SCFAs 
in autism comes from the increased prevalence of PPA-producing bacterial species in the 
intestinal tracts of ASD patients compared to healthy controls (Finegold et al., 2002; 
Finegold et al., 2010).
MacFabe and colleagues (2007; 2008; 2010) have found that the administration of 
PPA, as well as other short-chain fatty acids (SCFAs), has been found to produce ASD- 
like behavioural and neuropathological effects in rodents. In 2010, Thomas et al. added to 
the validity of the model by demonstrating that intracerebroventricular (ICV) infusions of 
PPA caused changes in the lipid profiles in the blood and brain tissue of rats that were 
consistent with the alterations in lipid profiles found in the blood of autistic patients (Bell, 
Sargent, Tocher, & Dick, 2000; Clark-Taylor & Clark-Taylor, 2004). Interestingly, 
though PPA is a regular byproduct of cellular metabolism and is produced by anaerobic 
fermentation in the gut, it is also produced at increased levels by bacterial species such as 
Clostridial species that are present in the intestinal tracts of ASD patients but not present 
in controls (Finegold et al., 2002). These traits suggest that PPA and other SCFAs might 
be a potential link between the behavioural, gut, metabolic, and immune factors implicated 
in autism.
Studies using the PPA rodent model of autism have produced behavioural, 
neuropathological, biochemical, and electrophysiological findings that are all consistent 
with what is seen in ASD (MacFabe et al., 2007; MacFabe et al., 2008; MacFabe et al., 
2011; Shultz et al., 2008; Shultz et al., 2009; Thomas et al., 2010). Behaviourally, traits 
such as bouts of hyperactivity, social impairments, perseveration, object fixation, and
66
repetitive movements have been observed. Electrophysiological findings have shown both 
caudate spiking associated with dystonia and limbic kindled seizures (MacFabe et al., 
2007). A clear innate neuroinflammatory response, as well as an increase in oxidative 
stress markers and altered lipid profiles, were seen in the brains of these rats, which have 
also been noted in autopsy data from human patients with ASD (Chauhan & Chauhan, 
2006; Vargas et al., 2005).
A study by Shultz et al. (2009) presented interesting findings using the PPA rodent 
model, wherein rats treated with brief intracerebroventricular infusions of PPA were able 
to learn the location of a hidden platform in the Morris water maze, but could not 
subsequently learn a new location of the platform. Animals in this experiment were given 
either three or five single infusions of PPA over the course of one week. Immediately 
following an infusion of the compound, animals were tested in the maze for acquisition, 
and then infused and tested one week later in a maze reversal task. Throughout reversal, 
the animals continued to return to the quadrant of the maze that initially housed the hidden 
platform, which is suggestive of perseverative behaviour (Shultz et al., 2009). This is 
consistent with the ritualistic and repetitive behaviours seen in patients with ASD (Sasson, 
Turner-Brown, Holtzclaw, Lam, & Bodfish, 2008). This finding lead to the investigation 
of the lasting cognitive effects of PPA after a brief period of recovery, where no PPA was 
administered.
In the previous study, Mepham et al. (2011) investigated the effects of PPA loading 
on the animals’ ability to succeed at a maze reversal task (i.e., to learn a new location of 
the hidden platform) when administration of the compound had been ceased for seven 
days (see Chapter 2). Based on the evidence of improvement and worsening in ASD, it
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was important to study the time course of the cognitive, behavioural, and 
neuropathological deficits induced by SCFAs in the PPA rodent model of autism. In the 
previous study, animals were tested for reversal of the water maze, following 7 days of 
PPA loading, in either the presence or absence of PPA. Results showed that not only were 
PPA-treated rats unable to acquire the maze properly, but they also were unable to reverse 
the maze. Ultimately, it was found that rats who received PPA on the day of maze 
reversal were unable to reverse the maze, whereas rats who were given PBS on reversal 
day learned the new location of the platform at the same level as controls, regardless of 
whether or not they had been loaded with PPA prior to acquisition (twice a day for seven 
days). Unlike the study by Shultz et al. (2009) that used only three or five single ICV 
infusions of PPA, it was concluded that two infusions per day for seven days was enough 
to disrupt cognitive functioning as measured in the Morris water maze. However, it was 
unclear which aspect of the task was being affected, and thus the nature of the observed 
impairment needed to be clarified. Water maze acquisition involves two main 
components. The first component is the learning of the behavioural strategies necessary 
for solving this task (Cain & Boon, 2003). This includes learning that the hidden platform 
is the only possible refuge from the pool, that attempts to climb out of the pool need to be 
suppressed, and that the platform is never located near the wall. Although rats are 
naturally very adept swimmers, they still experience a great deal of stress in the pool 
(Beiko, Lander, Hampson, & Cain, 2004) and the advanced learning of these behavioural 
strategies acts to alleviate some of this stress. The second component of water maze 
acquisition is the spatial learning component, which is generally the basis of how water 
maze data is interpreted. This aspect of the task deals with the animal’s ability to learn the
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actual spatial location of the platform from any release point, based on the visual cues 
around the room (Cain & Boon, 2003). In order for the animal to successfully learn the 
spatial aspect of the maze, it must first acquire the behavioural skills necessary to 
complete the maze. From an interpretation perspective, it is beneficial to differentiate 
between the two components in order to understand exactly which processes are being 
affected by the experimental treatment.
Given that there are two distinct components of water maze acquisition, it was 
important to investigate which aspect of maze performance was being disrupted by PPA 
administration. The aim of the current study, therefore, was to examine the effects of PPA 
loading on maze acquisition and reversal in animals that had previously been exposed to 
nonspatial pretraining in the maze, prior to drug treatment. Nonspatial pretraining is a 
technique designed to teach the animals the behavioural strategies necessary for 
successfully completing the maze, without having the rat learn a specific spatial location 
of the platform (Cain & Boon, 2003). Allowing the animals to be trained in the maze 
without learning a spatial location of the platform was expected to give a better indication 
of whether PPA treatment was interfering with strategies learning or spatial learning. It 
was hypothesized that nonspatial pretraining would improve the performance of PPA- 
treated animals in the water maze by allowing them to learn the behavioural strategies 




Subjects were 26 adult male Long-Evans hooded rats obtained from Charles River
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Laboratories (Quebec, Canada) and weighed between 200 and 250 g. Rats were 
housed in pairs in standard acrylic cages (26 cm x 48 cm x 21 cm) in a temperature 
controlled colony room (21 + 1.0 °C), and were naive to all experimental procedures.
After surgery, rats were housed individually and allowed to recover for 7-14 days, with no 
treatment taking place during this time. The light/dark schedule was a 12:12 cycle with 
lights on at 07:00 h and animals were allowed access to food (Prolab rat chow) and water 
ad libitum. All test procedures and experimentation were carried out in accordance with 
guidelines of the Canadian Council on Animal Care (CCAC) and approved by the 
University of Western Ontario Animal Use Committee.
3.2.2 Surgery: Cannula Implantation
Animals were implanted with a 23 gauge intracerebroventricular guide cannula 
using standard stereotaxic techniques. Rats were anaesthetized using inhaled 5% 
isoflurane and 2 L/min oxygen flow. While in the stereotaxic device, rats were equipped 
with a gas anaesthesia nose cover to maintain anaesthetic throughout surgery with 3% 
isoflurane and 500 mL/min oxygen flow. Under aseptic conditions, rats were implanted 
with a guide cannula in the right lateral ventricle, with the tip of the guide cannula at the 
following coordinates with reference to Bregma: anterior/posterior -1.4 mm; medial/lateral 
1.8 mm; dorsal/ventral -3.0 mm (Paxinos & Watson, 1986). Four small, stainless steel 
screws were inserted into the skull surrounding the cannula to provide anchors for dental 
acrylic, which attached the cannula to the skull. The cannula was sealed with a removable 
plug until the time of infusion. Immediately post-surgery, all rats received a subcutaneous 
injection of Ketoprofin (1 mL/kg) as an analgesic.
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3.2.3 Treatment Groups:
Rats were intracerebroventricularly infused with either phosphate buffered saline 
(PBS; 4 uL of 0.1 M solution) or propionic acid (PPA; 4 uL of 0.26 M solution).
Propionic acid was buffered to a physiological pH of 7.4 using hydrochloric acid or 
sodium hydroxide. Treatment was divided into two phases: Phase I and Phase II to yield 4 
treatment groups. The rats receiving PBS during Phase I followed by PBS during Phase II 
were labeled PBS-PBS (n = 6). Rats receiving PPA during Phase I and PPA during Phase 
II were labeled PPA-PPA (n = 8). Rats in the PPA-PBS group received PPA during Phase 
I and PBS during Phase II (n = 6), and vice versa for rats in the PBS-PPA group (n = 6). 
During Phase I, animals received two infusions of their assigned substance per day, at 
09:00 h and 13:00 h, for seven days. For one week after these 14 infusions, the rats were 
allowed a period of rest, where no treatment took place.
On the day following the rest period, Phase II, rats were given two more infusions of 
either the same compound that they received during Phase I (PBS-PBS and PPA-PPA 
groups), or of the compound they did not receive during Phase I (PPA-PBS and PBS-PPA 
groups). Doses were chosen based on previous dose-response findings from earlier 
studies done in our lab (MacFabe et al., 2007; Shultz et al., 2008).
3.2.4 ICVInfusions
Each rat received infusions of its assigned compound directly into the right lateral 
ventricle via a 30-gauge injection cannula connected to a Sage syringe pump by PE10 
tubing. The tip of the injection cannula protruded 0.5 mm beyond the tip of the guide 
cannula. Each infusion consisted of 4 uL of solution delivered over a period of 1 min. To 
ensure that the entire infusion had been delivered, the injection cannula was allowed to
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remain in place for an additional minute before being removed. On behavioural testing 
days, infusions were given approximately 3-5 minutes prior to the test session.
2.2.5 Behavioural Test Apparatus
2.2.5.1 Open Field Apparatus. Locomotor activity was monitored in an 
EthoVision circular open-field arena (90 cm diameter, 40 cm high) with Beta Chip 
bedding covering the floor of the arena. A CD camera and a darkroom lamp were 
mounted above the centre of the arena. The camera was connected to a computer, 
allowing behaviour to be recorded using the EthoVision 3.0.15 Behavioral Monitoring and 
Analysis System at a rate of 5.994 frames/s. This program is capable of tracking the x-y 
coordinates of each animal and it allows for the computation of several quantitative 
variables. The camera was also connected to a VCR, allowing behaviour to be recorded 
onto VHS for later analysis.
2.2.5.2 Water Maze. Spatial cognition was assessed using a water maze consisting 
of a circular pool (1.5 m in diameter, 45 cm deep) filled with tap water at 29 + 1.0 °C. 
Hidden approximately 2 cm below the water surface was an escape platform (9 cm x 9 
cm). The platform was located in the centre of the south-east quadrant during acquisition 
(Phase I), and in the centre of the north-west quadrant during reversal (Phase II). 
Polypropylene pellets floating on top of the water prevented the rats from seeing the 
hidden platform by making the surface opaque (Cain, Hargreaves, Boon, & Dennison, 
1993). Pictures and objects around the room provided a variety of distal cues. Behaviour 
was recorded by a video camera mounted to the ceiling above the pool. The camera was 
connected to a computer and behaviour was objectively analyzed by an automated
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tracking system that digitized each swim trial {Poly-Track, San Diego Instruments, San 
Diego, CA).
3.2.6 Experimental Procedure
3.2.6.1 Non-Spatial Pretraining. Pretraining was carried out one week after cannula 
implantation surgery. Pretraining took place on one day, day 0, when rats were given 10 
trials each with a 5 minute intertrial interval. Only one rat swam in the pool at a time. For 
nonspatial pretraining, thick black curtains, attached to a circular track mounted to the 
ceiling, were drawn completely around the pool, eliminating all distal cues. The visible 
portion of the ceiling above the pool was uniform and provided no directional cues. The 
hidden platform was moved to a new quadrant after every pretraining trial. A rat was 
introduced into the pool and swam until it found the hidden platform or 120 s elapsed, at 
which time it was placed on the platform where it remained for 30 s. Swimming was 
observed on the television monitor, and search times were recorded. The acquisition of 
water maze behavioural strategies during pretraining has been documented (Cain, Boon, & 
Corcoran, 2006; Perrot-Sinal, Kosteniuk, Ossenkopp, & Kavaliers, 1996).
3.2.6.2 Phase I. During Phase I, rats received infusions of their assigned drug twice 
a day for 7 days. On the final day of infusions, day 7, the rats were tested in the open field 
apparatus in the morning, following their first infusion. Each rat was placed individually 
into the open field and behavioural data were collected for 30 minutes. In the afternoon, 
following the second infusion of the day, rats were tested in the water maze. Behavioural 
testing commenced within approximately 3-5 minutes of the infusion.
Rats were given 10 training trials in the water maze. Each trial began with the rat 
being placed in the pool, adjacent to, and facing, the pool wall at one of 4 quasi-random
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start locations (north, east, south, or west), and ended when the rat stood on the hidden 
platform. The platform was located in the centre of the south-east quadrant during maze 
acquisition. Rats that failed to reach the hidden platform within 60 s of the 
commencement of the trial were guided to the platform by the experimenter. Rats 
remained on the platform for 15 s before they were placed in a drying chamber that was 
heated from above by an infrared lamp. Due to metabolic clearance rates of the injected 
substances, rats were run in squads of 4 so that the inter-trial interval for the 10 acquisition 
trials was not more than 5 min. For graphic presentation of water maze variables, the time 
to reach the platform was averaged for every block of two trials (e.g. Block 1 = (Trial 1 + 
Trial 2)12. Following acquisition training in the water maze, rats were given no treatment 
for one week.
3.2.6.3 Phase II. Phase II consisted of one day of infusions (at 09:00 h and 13:00 h) 
and testing and occurred one week after the conclusion of Phase I. Rats again received 
two infusions of either PBS or PPA, with half of the rats receiving the infusion type (PBS 
or PPA) that they had not received during Phase I (i.e., PPA-PBS and PBS-PPA groups). 
Following the morning infusion, rats were once again placed in the open field apparatus 
for 30 minutes, and behavioural data was collected.
After the afternoon infusion, the rats were again tested in the water maze, following 
the same procedure as on the 7th day of Phase I. However, the platform was now located in 
the north-west quadrant of the pool rather than the south-east quadrant, where it was 
located during maze acquisition.
3.2.7 Statistical Analysis o f  Behaviours
All statistical tests were calculated using SPSS 18.0 (SPSS, Inc.) for Windows.
74
Tests were completed using a = .05 as the criterion for significant effects.
3.2.7.1 Water Maze Search Latencies, Total Distance Traveled, Time Spent in 
Periphery, Swim Speed, Number o f  Direct and Circle Swims, and Percent First Choices to 
Initial Quadrant. Search latency was defined as the time in seconds from release until the 
rat climbed onto the hidden platform. Time spent in the periphery was calculated with the 
periphery being defined as the outer 33% of the pool. A direct swim was defined as a 
swim that remained entirely within an 18 cm wide virtual alley from the start point to the 
hidden platform without crossing over itself. A circle swim was defined as a swim that 
approximated an arc of a circle without exceeding 360 degrees or crossing over itself. 
Direct and circle swims are indicative of spatial place learning and were summed for each 
test session.
Data were analyzed using a mixed design analysis of variance (ANOVA) with drug 
treatment (PBS or PPA) as the between-subjects factor and trial (10 training trials) and test 
day (one or two) as the within-subjects factor. Student-Newman-Keuls (S-N-K) post-hoc 
tests were carried out to obtain group differences on individual trials.
3.2.7.2 Open Field Total Distance Traveled, Average Speed, and Time Spent in 
Periphery. Data were analyzed for main effects using a mixed design ANOVA with drug 
treatment (PBS or PPA) as the between-subjects factor and time bin (six 5-min time bins) 
and test day (one or two) as the within-subjects factor.
3.2.8 Monitoring o f  Convulsive Activity
Rats were closely monitored for possible convulsive behaviour. Past studies from 
our lab have found a kindling effect associated with repeated daily ICV infusions of PPA 
in some rats (MacFabe et al., 2007). The onset of seizures may be an issue in studies
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investigating cognition or sensorimotor ability if a seizure were to occur prior to, or during 
testing.
3.2.9 Tissue Preparation and Histology
The day after the reversal test day (Phase II), rats were deeply anaesthetized with 
sodium pentobarbital (270 mg/mL) and perfused transcardially with ice cold 0.1 M 
phosphate buffered saline (PBS, pH 7.5) followed by 4% paraformaldehyde in PBS. The 
brain was removed from the skull and placed in 4% paraformaldehyde solution to be 
stored at 4 °C for 24 h. Following the fixation period, brains were placed in 18% sucrose 
solution prior to paraffin embedding. Selected coronal blocks from various brain regions 
(frontal cortex/striatum and dorsal hippocampus) were dehydrated and defatted by 
increasing concentrations of ethanol/xylenes using standard histological procedures, and 
embedded in paraffin wax for permanent storage. Serial 4 um sections were obtained 
through the right lateral ventricle (cannula site) and the ipsilateral dorsal hippocampus, 
including adjacent white matter o f the external capsule. The sections were then stained 
using standard immunohistochemical procedures, for glial fibrillary acidic protein (GFAP; 
1:500, polyclonal, DakoCytomation, Glostrup, Denmark), a marker for reactive astrocytes 
in the central nervous system, and Iba-1 (1:10,000, rabbit polyclonal, Wako, Richmond, 
VA), a marker for activated microglia. Tissue sections were mounted on glass slides 
(SurgiPath, Canada) and dried overnight at 37°C. Sections were deparaffinized and 
rehydrated using standard immunohistochemical procedures for antigen recovery (Shi, 
Cote, & Taylor, 2001). Endogenous peroxidase activity was blocked using a 3% hydrogen 
peroxide in distilled water solution for 5 min. For antigen recovery, sections were 
immersed in boiling 0.21% citric acid buffer (pH 6.0) for 30 min in a 1250W microwave
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oven. Slides were counterstained with Gill haematoxylin (EMD Biosciences) and rinsed 
with PBS for 5 min. A 10% normal horse serum in PBS solution was applied for 5 min 
followed by the primary antibodies for 1 hr at room temperature. Following the incubation 
period, sections were washed with PBS and secondary antibodies, either biotinylated anti­
mouse IgG (Vector Laboratories, Burlingame, CA-BA2000) or biotinylated anti-rabbit 
(Vector Laboratories, Burlingame CA-BA1000) for 30 min. Tissues were again washed 
with PBS and stained using the avidin-biotin complex (Vectastain Elite ABC, Vector 
Laboratories, Burlingame, CA- PK6100) for 30 min at room temperature. Following 
incubation, slides were washed with PBS and 3, 3- diaminobenzidine DAB chromagen 
(Sigma-D8001) was applied for 5 min. After final rinsing, slides were dehydrated, 
cleared, and coverslipped.
Due the diffuse nature of GFAP and IbAl staining, analyses were completed by 
using the ‘area stained’ function within ImagePro Plus which sums the immunopositive 
area within a digital image to provide a total immunopositive area per picture (pm2).
3.3 Results
3.3.1 Baseline Locomotor Activity
There were no significant group differences among the drug groups for any of the 
variables measured prior to drug treatment.
3.3.2 Open Field Apparatus
3.3.2.1 Total Distance Traveled. In the open field apparatus, all rats traveled 
significantly less across time, F(5, 120) = 23.905, p  < .001. There was a main effect of 
drug, F{ 1, 24) = 32.320,/) < .001. There was also a significant interaction between time 
and treatment, F(5, 120) = 2.924, p  < .05. This indicates that PPA-treated rats traveled
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more across time and their total distances decreased less than PBS controls over the final 
25 minutes in the open field (Fig. 3.1a).
On reversal day, all rats once again traveled significantly less across time in the open 
field, .F(5, 110) = 17.659,/» < .001 (Fig. 3.1b). There was no significant main effect of 
drug, however , F(3, 22) = .181,/» = .908.
3.3.2.2 Average Speed. In the open field apparatus, all rats tended to travel at a 
higher speed in the beginning of the session compared to the end, F(5, 120) = 76.535, p  < 
.001. The PPA-treated group exhibited significantly greater average speeds than PBS 
controls across time, F (l, 24) = 45.959, p  < .001 (Fig. 3.2a). There was also a significant 
interaction between time and drug treatment, F(5, 120) = 2.769, p  < .05. PPA-treated rats 
traveled at higher speeds than controls over time, however, this difference decreased 
across time bins.
On reversal day, as seen in Fig. 3.2b, all rats once again traveled at significantly 
lower average speeds in the open field as the session progressed, F(5, 110) = 36.972, p  
< .001. There was no significant main effect of drug, however, with all groups traveling at 
similar speeds, regardless of drug treatment, F{3, 22) = .239,/» = .868.
3.3.3 Water Maze
3.3.3.1 Removal o f  Data from Convulsive Rats. Throughout the experiment, several 
rats experienced convulsive activity during acquisition of the water maze, which occurred
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Figure 3.1 Total distance (cm) traveled on Acquisition day (A) and total distance 
traveled on Reversal day (B) for rats injected (ICV) with either PBS (vehicle) or PPA 
(0.26M). Each point represents group mean data for each time bin in the 30 minute 
session immediately following injection. Error bars represent + SEM. * p < .05. On 
Acquisition day, PPA-treated animals traveled significantly greater distances than 
controls over the last 25 minutes in the open field. There were no significant group 
differences found on Reversal day.
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Figure 3.2 Average speed (cm/s) in the open field apparatus on Acquisition day (A) 
and average speed on Reversal day (B) for rats injected (ICV) with either PBS 
(vehicle) or PPA (0.26M). Each point represents group mean data for each time bin 
in the 30 minute session immediately following injection. Error bars represent + 
SEM. * p < .05. PPA-treated rats exhibited significantly greater average speeds, 
and their average speeds decreased less across trials than PBS controls on 
Acquisition day. There were no significant group differences on Reversal day.
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immediately following infusion. This is a common feature of rats subjected to this 
particular infusion schedule. Because of the nature of the task, the data collected from 
these rats was excluded from water maze analyses. In total, water maze data from five rats 
was excluded.
33.3.2 Search Latencies on Pretraining Trials. During nonspatial pretraining in the 
water maze, there was a significant effect of pretraining trial, F(9, 216) = 7.997, p  < .001, 
indicating that all animals learned the strategies necessary to solve the maze. By dividing 
the rats into drug groups based on the treatment they would receive following pretraining, 
there were no significant group differences, F (l, 24) = .511,p  = .875 (Fig. 3.3). This 
suggests that groups who would receive PPA during Phase I were able to learn the 
strategies of the maze just as well as control rats.
3.3.33 Search Latencies. During acquisition training, both treatment groups 
exhibited decreased search times as training progressed. However, performance of the 
PPA-treated rats improved less than the PBS controls. These impressions were confirmed 
by ANOVA, with significant main effects being found for both trial, F(9, 171) = 9.129, p  
< .001, and drug treatment F (l, 19) = 15.596 , p<  .01. There was found to be no 
significant interaction between trial and treatment, F(9, 171) = .992, p  = .423 (Fig. 3.4a).
On reversal Day, as shown in Fig. 3.4b, all treatment groups exhibited decreased 
search times as training progressed, F(9, 153) = 6.961 >P< .001. There was a significant 
main effect of drug treatment, F(3, 17) = 5.985,p  < .01. There was found to be no 
significant interaction between trial and treatment, F(27, 153) = 1.533, p  = .129, indicating 
that the improvement across trials was similar across drug groups.
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Figure 3.3 Search latencies (s) during pretraining trials for untreated rats. Each 
point represents group mean data for each of 10 pretraining trials. Error bars 
represent + SEM. Search latencies of all rats decreased across pretraining trials, 
with no group differences between rats who were subsequently given PPA and 
those who were subsequently given PBS.
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Pretraining Trials in W ater Maze
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Figure 3.4 Search latencies (s) to find the hidden platform on Acquisition day (A) 
and on Reversal day (B) for rats injected with either PBS (vehicle) or PPA (0.26M). 
Each point represents group mean data for each of 10 trials immediately following 
injection. Error bars represent + SEM. There was a significant main effect of drug 
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3.3.3.4 Total Distance Traveled. During acquisition training, all treatment groups 
exhibited decreased distances traveled as training progressed. However, distances traveled 
by PPA-treated rats decreased less overall than the PBS controls. These impressions were 
confirmed by ANOVA, with significant main effects being found for both trial, F{9, 171)
= 6.183 ,/? < .001, and treatment F (l, 19) = 16.876,/? < .01. There was found to be no 
significant interaction between trial and treatment, F(9, 171) = 1.225,/? = .305 (Fig. 3.5a).
On reversal Day, as shown in Fig. 3.5b, all treatment groups exhibited decreased 
distances traveled across trials, F(9, 153) = 4.816,/? < .01. However, groups receiving 
PPA on reversal day continued to travel larger distances than animals given PBS, F (l, 17) 
= 6.294,/? < .01. There was found to be no significant interaction between trial and 
treatment, F(27, 153) = 11.674,/? = .088, indicating that the improvement across trials was 
similar across drug groups.
3.3.3.5 Time Spent in the Periphery. During acquisition training, all treatment 
groups exhibited decreased time spent in the periphery of the pool as training progressed. 
However, PPA-treated rats continued to spend more time in the periphery than the PBS 
controls, as seen in Fig. 3.6a. These impressions were confirmed by ANOVA, with 
significant main effects being found for both trial, F(9, 171) = 8.110,/? < .001, and drug 
treatment F( 1, 19) = 8.399,/? < .01. There was found to be no significant interaction 
between trial and treatment, F(9, 171) = 1.468,/? = .213.
On reversal Day, all treatment groups exhibited decreased time spent in the 
periphery of the pool across trials, F(9, 153) = 6.775, p  < .01. There was also a main 
effect of drug, F(3, 17) = 4.809,/? < .05 (Fig. 3.6b). There was found to be no significant
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Figure 3.5 Total distance (cm) traveled in the water maze on Acquisition day (A) 
and on Reversal day (B) for rats injected with either PBS (vehicle) or PPA (0.26M). 
Each point represents group mean data for each of 10 trials immediately following 
injection. Error bars represent + SEM. PPA-treated rats traveled significantly 
greater distances on Acquisition day. On Reversal day, groups receiving PPA 
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Figure 3.6 Time spent in the periphery (s) of the water maze on Acquisition day (A) 
and on Reversal day (B) for rats injected with either PBS (vehicle) or PPA (0.26M). 
Each point represents group mean data for each of 10 trials immediately following 
injection. Error bars represent + SEM. The periphery represents the outer third of 
the pool. On Acquisition day, PPA-treated rats spent more time in the periphery 
compared to controls. On Reversal day, there was a main effect of drug treatment 
on the amount of time spent in the periphery.
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interaction between trial and drug treatment, F(27, 153) = 1.122,p  = .364, indicating that 
the improvement across trials was similar across drug groups.
3.3.3.6 Number o f  Direct and Circle Swims. As shown in Fig. 3.7a, during 
acquisition training the PPA-treated group exhibited fewer direct and circle swim paths 
than PBS controls. ANOVA confirmed this impression, revealing a significant drug 
treatment effect, F( 1, 19) = 6.494,/? < .05, with the PPA group displaying fewer direct and 
circle swims than PBS controls.
During reversal training, there was a significant main effect of group, F(3, 17) = 
5.537,/?<.01 (Fig. 3.7b).
3.3.4 Neuropathological Data
3.3.4.1 Reactive Astrocytes. Coronal sections from three different brain areas 
(dentate gyrus, dorsal hippocampus -  CA2 region, and white matter) were stained with 
glial fibrillary acidic protein (GFAP), which is a marker for reactive astrocytes. There was 
a significant main effect of drug treatment on GFAP staining in the white matter, F{3, 22) 
= 5.779, p  < .01. There were no significant group differences in the dentate, F(3, 22) = 
2.310,/? = .104, or in the hippocampus, F(3, 22) = .816,/? = .499 (Fig. 3.8).
3.3.4.2 Activated Microglia. Sections from the same brain areas mentioned above 
were also stained for Iba-1, a marker for activated microglia. There were no significant 
group differences in any of the brain areas analyzed (Fig 3.9).
3.4 Discussion
This study examined the effects of nonspatial pretraining on water maze 
performance following PPA infusion. It was found that PPA loading (i.e., ICV infusion
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Figure 3.7 Number of direct and circle swims on Acquisition day (A) and on 
Reversal day (B) for rats injected with either PBS (vehicle) or PPA (0.26M). Each 
bar represents group mean data immediately following injection. Error bars 
represent + SEM. * p < .05. Rats treated with PPA exhibited significantly fewer 
direct and circle swims than controls. On reversal day, there was found to be a 
significant main effect of drug treatment on the number of direct and circle swims.
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Figure 3.8 Glial fibrillary acidic protein (GFAP) staining for rats injected with either 
PBS (vehicle) or PPA (0.26M). GFAP is a marker for reactive astrocytes. Three 
different brain areas were assessed: the dentate, the CA2 region of the 
hippocampus, and white matter. Each point represents group mean data. Error
bars represent + SEM. * Refers to a significant group difference in the total mean 
area stained by GFAP in the white matter, with PPA-PPA and PPA-PBS groups 














Figure 3.9 lba-1 staining for rats injected with either PBS (vehicle) or PPA (0.26M). 
lba-1 is a marker for activated microglia. Three different brain areas were assessed: 
the dentate, the CA2 region of the hippocampus, and white matter. Each point 
represents group mean data. Error bars represent + SEM. There were no group 














twice a day for seven days) was sufficient to severely disrupt cognitive functioning as 
measured in the water maze (see Chapter 2). Not only did PPA treatment interfere with 
water maze acquisition, but it was also found that two infusions of the compound alone 
were sufficient to affect the animals’ ability to reverse the maze. While it was concluded 
that the cognitive effects caused by PPA were not entirely permanent, as animals given 
vehicle on reversal day were able to perform as well as controls, it was still necessary to 
dissociate the two possible water maze processes that may have been affected by PPA 
treatment. Successful water maze performance involves first learning the behavioural 
strategies necessary to solve the maze, then learning the actual spatial location of the 
platform in the maze. Nonspatial pretraining allows the animals to gain experience in the 
former, without being trained for the latter (Morris, 1989). This previous experience 
allows for the dissociation of the two components when interpreting the findings.
3.4.1 Water Maze Acquisition
Pretrained rats subsequently treated with PPA had difficulty acquiring the maze. 
They exhibited longer search latencies, greater total distances traveled, more time spent in 
the periphery of the pool, and fewer direct and circle swims compared to pretrained 
controls. Together, these findings indicate that even when animals have been nonspatially 
pretrained in the maze, PPA treatment still had an effect on the cognitive processes 
measured in the water maze. Search latencies during pretraining, combined with the 
significant improvement in performance across trials during pretraining, suggest that all 
animals were able to learn these behaviours throughout the pretraining trials. Following 
the seven days of infusions, the PPA-treated animals were not able to perform at the same 
level as controls, even when nonspatially pretrained. Interestingly, a significant effect of
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pretraining on strategies used was observed, wherein pretrained groups (given PBS or 
PPA) showed more direct and circle swims compared to non-pretrained groups (F(\, 33) = 
29.035 , p <  .001). This demonstrates that PPA-treated rats retained some aspects of their 
nonspatial pretraining, yet still remained at a lower level of performance than controls.
Due to the lack of significant group differences in swim speed (data not shown), this 
deficit is likely not a result of motor impairments caused by PPA treatment. This pattern 
of impairment, even after nonspatial pretraining, has rarely been reported. A study by 
Morris (1989) reported that chronic administration of D,L-2-amino-5-phosphonopentanoic 
acid (AP5, a potent and selective NMDA receptor antagonist) during water maze 
acquisition training caused pretrained AP5 rats to exhibit shorter search latencies than 
non-pretrained AP5 rats. However, the pretrained AP5 rats in this study still performed at 
a lower level than controls. Morris (1989) concluded that pretraining decreased the 
sensorimotor deficits caused by the drug, but had no effect on the drug-induced spatial 
learning impairment in the maze.
Saucier et al. (1996) investigated the effects of NMDA antagonism on water maze 
performance. It was found that naive (i.e., non-pretrained) drug-treated rats showed 
certain sensorimotor disturbances that were not seen in control rats. These disturbances 
included swimming excessively in the periphery, jumping or deflecting off of the 
platform, and swimming over the platform rather than mounting it. These behaviours 
were thought to have been the result of hyperactivity caused by the antagonist and would 
have increased the search latencies exhibited by this group. Their data suggest that as 
sensorimotor disturbances increase, maze acquisition scores decrease (Saucier et al.,
1996). Based on these findings, it would be wise to thoroughly investigate any
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sensorimotor disturbances that may be present in PPA-treated rats. It has been shown that 
PPA can cause both hyperactivity and motor abnormalities (MacFabe et al., 2007,
MacFabe et ah, 2008), and so it is possible that this could have presented as sensorimotor 
disturbances such as those reported by Saucier et ah (1996), causing impairments in 
overall acquisition. A significant main effect of group was seen in the amount of time 
spent in the periphery of the pool on acquisition day, suggesting that the inefficient 
strategy of thigmotaxic swimming in these animals could have been responsible for their 
inferior performance in the maze. There was also observational evidence of other 
sensorimotor dysfunction in these animals, such as platform swimovers and jumping off of 
the platform, but these data were not quantified for the purposes of the present study. 
Findings by Saucier et ah (1996) and Morris (1989) suggest that these sensorimotor 
deficits may have been a causal factor in the impairments seen in the maze, even following 
pretraining. Deficits seen in the present study may have been the result of PPA-induced 
sensorimotor disturbances rather than a specific spatial learning deficit, similar to what 
was seen by Saucier et ah (1996).
Overall, rats in the present study were still unable to acquire the maze, even though 
they had learned the necessary behavioural strategies beforehand in nonspatial pretraining. 
Although PPA-treated rats were impaired on many measures in the maze, they did exhibit 
a higher percentage of direct and circle swims compared to naive (non-pretrained) PPA- 
treated rats from Experiment 1 (see Chapter 2). This indicates that they were able to apply 
some of the behavioural strategies acquired in pretraining.
3.4.2 Water Maze Reversal
During reversal of the maze, findings were less clear-cut. Rats treated with PPA on
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reversal day were impaired compared to controls on measures of search latency, total 
distance traveled, and percentage of direct and circle swims. Interestingly, rats in either 
the PBS-PPA or PPA-PPA groups were intermediate in their level of performance on 
certain measures, as was seen in search latencies and time spent in the periphery, 
respectively. This might indicate that, while two infusions of PPA were sufficient to cause 
impairments on most measures, two infusions were not sufficient to cause impairments in 
search latencies or periphery swimming when the animals had experience in the maze.
Again on reversal day, as in Experiment 1 (see Chapter 2), there was no main effect 
of group on the percentage of first choices made to the initial quadrant (data not shown). 
This suggests that the animals were not impaired due to perseveration in returning to the 
initial location of the platform, as was reported by Shultz et al. (2009). The current study 
was designed to investigate the lasting effects of PPA on cognition. Shultz et al. (2009) 
provided evidence that brief ICV administration of PPA caused perseveratory behaviours 
that interfered with the animals’ ability to reverse the water maze. As animals in the 
present study failed to acquire the maze to begin with, it was not possible to determine 
whether or not they exhibited perseveratory behaviours later on in the experiment, using 
the current experimental design.
3.4.3 Convulsive Activity
Several animals displayed convulsive activity in the water maze during acquisition. 
Due to the nature of the task and the potential interference that convulsive activity may 
have caused in the animals’ ability to learn the maze, data from these five rats (out of a 
total of 26 rats) was removed from all water maze analyses. Although the presence of 
convulsive activity does not guarantee the occurrence of seizure activity, these data were
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removed to be conservative. One caveat is that in removing data from rats that displayed 
convulsions, the data that were included in the analyses in essence came from animals that 
were resistant to PPA-induced convulsions. Animals that were resistant to the 
demonstrated electrophysiological effects of PPA (MacFabe et al., 2007) were selected for 
in this analysis and this cannot be ruled out as a potential confound. A subgroup of these 
rats is more sensitive to PPA on a number of behavioural and pathological variables 
(MacFabe -  personal communications), as is the case in human populations. Similarly, 
although many animals did not exhibit outward signs of convulsive activity, this does not 
necessarily mean that they did not experience seizure activity (e.g., immobility associated 
with hippocampal seizures). This can only be confirmed electroencephalographically.
3.4.4 Open Field
Animals treated with PPA showed increased distances traveled and increased 
average velocities compared to controls on the seventh day of infusions (acquisition day). 
This is suggestive of hyperactivity, which is consistent with previous studies using the 
PPA rodent model of ASD (MacFabe et al., 2007; MacFabe et al., 2008; Thomas et al., 
2010). Interestingly, there was no difference in the amount of time spent in the periphery 
of the arena based on drug treatment. This is inconsistent with previous findings of 
increased anxiety in the model (MacFabe et al., 2007; MacFabe et al., 2008; Shultz et al. 
2008). Thigmotaxis, spending time in the periphery of an arena or pool, is commonly 
viewed as a measure of anxious behaviour in rodents. Animals given PPA did not exhibit 
increases in this anxiety-related behaviour compared to controls. This finding was 
inconsistent with the findings from Chapter 2, where PPA animals spent significantly 
more time in the periphery of the open field apparatus compared to controls on acquisition
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day. This may have been a result of the vast amount of handling that the animals had 
experienced by this point in the present experiment, which included a day of pretraining in 
the maze that animals in the previous study did not experience. It is possible that the 
animals were so habituated to experimental procedures by this seventh day of 
experimentation that they no longer felt increased levels of anxiety compared to controls.
On reversal day, there were no group differences on any of the variables measured in 
the open field apparatus. This indicates that, regardless of initial drug treatment during 
Phase I, one infusion of PPA was not sufficient to cause hyperactivity or anxiety on 
reversal day. The lack of significant group differences also suggests that the effects seen 
on acquisition day as a result of PPA loading did not persist during the week of 
“recovery”. This may indicate that the effects seen on acquisition day were not permanent 
and were able to be returned to baseline over time, once PPA treatment had been stopped.
3.4.5 Neuropathological Data
There was a significant increase in reactive astrocytes in the white matter of rats 
from the PPA-PPA and PPA-PBS groups, compared to controls. Reactive astrogliosis in 
animals from the PBS-PPA group was not found to be significantly different than any 
other group. These findings suggest that PPA loading (i.e., two infusions per day for 
seven days) causes persistent astroglial inflammation, even after a week of no infusions. 
According to Vargas et al. (2005), post-mortem studies of brain tissue of autistic patients 
showed increased levels of GFAP immunostaining relative to controls in the three regions 
of the brain that were examined: dorsal hippocampus and adjacent white matter of the 
external capsule. The most marked astroglial reactivity was seen in the granular cell layer 
of the cerebellum, as well as the cerebellar white matter. Overall, the authors concluded
that there is an innate neuroinflammatory response present in the brains of autistic 
patients, characterized by activation of microglial and astroglial cells in the cerebral cortex 
and the cerebellum (Vargas et al., 2005). A significant group difference in microglial 
activation was not found in the present study. The lack of significant group differences on 
this measure could signify that there was no activation of microglia as a result of PPA 
infusion. MacFabe and colleagues (2007; 2008), however, found significant microglial 
and astroglial activation in the brain tissue of rats that had been infused with 0.26M PPA 
twice a day for thirteen consecutive days, and then sacrificed immediately. This suggests 
that the lack of group differences in the present study was not indicative of the absence of 
microglial activation altogether, but rather evidence for microglial “recovery” following 
the cessation of PPA treatment, as activation of microglia has been well documented in the 
model.
Overall, the neuropathological findings in the present study suggest that the majority 
of the inflammation caused by PPA infusion (MacFabe et al., 2007; MacFabe et al., 2008) 
returns statistically to baseline after one week of no infusion, with the exception of 
astrogliosis in the white matter of these animals, which seems to persist. Due to the 
present lack of research on recovery in ASD, as well as the nature of post-mortem studies, 
the innate neuroinflammatory response characteristic of ASD has not yet been explored in 
“recovered” patients. The current findings suggest, however, that this pattern of 
inflammation may return to baseline after cessation of PPA treatment.
3.4.6 Return to Baseline After Cessation o f  PPA Treatment
The purpose of this study was to examine the effects of nonspatial pretraining on the 
ability of PPA-treated rats to acquire the Morris water maze and whether or not the
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observed cognitive deficits caused by PPA would return to baseline after drug treatment 
had been discontinued. The concept of “recovery” in autism has not yet been extensively 
studied and is just beginning to become an area of interest for ASD researchers. Though 
the definition of “recovery” is varied and not widely agreed upon, Helt et al. (2008) 
defined it as the loss of the behavioural characteristics of ASD. They do not suggest that 
these children recover to a state of “normalcy”, but that they reach a level where they are 
learning and applying new skills at an appropriate age and developmental level for that 
child (Helt et al., 2008).
PPA treatment has been shown to cause behavioural, biochemical, and 
neuropathological changes in rodents that are consistent with characteristics seen in ASD 
(MacFabe et al., 2007, MacFabe et al., 2008; MacFabe et al., 2011; Shultz et al., 2008; 
Shultz et al., 2009; Thomas et al., 2010). These widespread effects of PPA had not yet 
been looked at on a long-term basis prior to the present study. By infusing rats with PPA 
twice a day for seven days, and then allowing a week of “recovery”, where no PPA was 
administered, it was possible to examine the effects of the initial PPA loading followed by 
a period of PPA discontinuation. For the most part what was seen was a return to baseline 
by these animals, on most variables measured in the open field, the water maze, and 
histological analysis. Rats that were infused with PPA initially and then subsequently 
infused with PBS vehicle on reversal day, after a seven-day period of “recovery” showed 
no impairments in the water maze or open field compared to controls. As groups 
receiving PPA on reversal day were most often not significantly different, regardless of 
initial drug treatment, it appears as though the effects of PPA loading are not permanent.
107
3.5 References
Arndt, T. L., Stodgell, C. J., & Rodier, P. M. (2005). The teratology of autism. 
International Journal o f  Developmental Neuroscience , 23, 189-199.
Ashwood, P., & Van de Water, J. (2004). Is autism an autoimmune disease? Autoimmunity 
Reviews, 3, 557-562.
Beiko, J., Lander, R., Hampson, E., Cain, D.P. (2004). Contribution of sex differences in 
the acute stress response to sex differences in water maze performance in the rat. 
Behavioural Brain Research, 757(1-2), 239-253.
Bell, J.G., Sargent, J.R., Tocher, D.R., & Dick, J.R. (2000). Red blood cell fatty acid 
compositions in a patient with autistic spectrum disorder: A characteristic abnormality in 
neurodevelopmental disorders? Prostaglandins, Leukotrienes, and Essential Fatty Acids, 
63, 21-25.
Besag, F.M. (2004). The department of health action plan “improving services for people 
with epilepsy”: A significant advance or only a first step? Seizure, 73(8), 553-564.
Brock, M., & Buckel, W. (2004). On the mechanism of action of the antifungal agent 
propionate. European Journal o f  Biochemistry, 271, 3227-3241.
Cain, D.P., & Boon, F. (2003). Detailed behavioral analysis reveals both task strategies 
and spatial memory impairments in rats given bilateral middle cerebral artery stroke. Brain 
Research, 972, 64-74.
Cain, D.P., Hargreaves, E.L., Boon, F., & Dennison, Z. (1993). And examination of the 
relations between hippocampal long-term potentiation, kindling, afterdischarge, and place 
learning in the water maze. Hippocampus, 3(2), 153-163.
Calabrese, V., & Rizza, V. (1999). Formation of propionate after short-term ethanol 
treatment and its interaction with the carnitine pool in rat. Alcohol, 19, 169-176.
Centers for Disease Control & Prevention. (2009). Prevalence of Autism Spectrum 
Disorders - Autism & Developmental Disabilities Monitoring Network. MMWR 
Surveillance Summaries, 58 (SS-10), 1-20.
Chauhan, A., & Chauhan, V. (2006). Oxidative stress in autism. Pathophysiology, 13, 171- 
181.
Clark-Taylor, J.T., & Clark-Taylor, B.E. (2004). Is autism a disorder of fatty acid 
metabolism? Possible dysfunction of mitochondiral beta oxidation by long chain acyl-CoA 
dehydrogenase. Medical Hypotheses, 62, 970-975.
Coulter, D. L. (1991). Carnitine, valproate, and toxicity. Journal o f  Child Neurology, 6, 7- 
14.
108
Curtis, J.T., Hood, A.B., Chen, Y., Cobb, G.P., & Wallace, D.R. (2010). Chronic metals 
ingestion by prairie voles produces sex-specific deficits in social behavior: An animal 
model of autism. Behavioural Brain Research, 213, 42-49.
DeCastro, M., Nankova, B. B., Shah, P., Patel, P., Mally, P. V., Mishra, R., et al. (2005). 
Short chain fatty acids regulate tyrosine hydroxylase gene expression through a cAMP- 
dependent signaling pathway. Brain Research Molecular Brain Research, 142, 28-38.
DiCicco-Bloom, E., Lord, C., Zwaigenbaum, L., Courchesne, E., Dager, S. R., Schmitz, 
C., et al. (2006). The developmental neurobiology of autism spectrum disorder. The 
Journal o f  Neuroscience , 62, 6897-6906.
Fallon, J. (2005). Could one of the most widely prescribed antibiotics 
amoxicillin/clavulanate "augmentin'' be a risk factor for autism? Medical Hypotheses, 64, 
312-315.
Fatemi, S. H., Cuadra, A. E., El Fakahany, E. E., Sidwell, R. W., & Thuras, P. (2000). 
Prenatal viral infection causes alterations in nNOS expression in developing mouse brains. 
Neuroreport, 11, 1493-1496.
Finegold, S. M., Song, Y., & Liu, C. (2002). Taxonomy-general comments and update on 
taxonomy of Clostridia and Anaerobic cocci. Anaerobe , 8, 283-285.
Hara, H., Haga, S., Aoyama, Y., & Kiriyama, S. (1999). Short-chain fatty acids suppress 
cholesterol synthesis in rat liver and intestine. Journal o f  Nutrition, 129, 942-948.
Helt, M., Kelley, E., Kinsbourne, M., Pandey, J., Boorstein, H., Herbert, M., & Fein, D. 
(2008). Can children with autism recover? If so, how? Neuropsychological Review, 18, 
339-366.
Herbert, M. R., Russo, J. P., Yang, S., Roohi, J., Blaxill, M., Kahler, S. G., et al. (2006). 
Autism and environmental genomics. Neurotoxicology, 27, 671-684.
Horvath, K., Papadimitriou, J. C., Rabsztyn, A., Drachenberg, C., & Tildon, J. T. (1999). 
Gastrointestinal abnormalities in children with autistic disorder. Journal o f  Pediatrics, 
135, 559-563.
Hu, V. W., Frank, B. C., Heine, S., Lee, N. H., & Quackenbush, J. (2006). Gene 
expression profiling of lymphoblastoid cell lines from monozygotic twins discordant in 
severity of autism reveals differential regulation of neurologically relevant genes. BMC 
Genomics, 7, 118.
Ingram, J. L., Peckham, S. M., Tisdale, B., & Rodier, P. M. (2000). Prenatal exposure of 
rats to valproic acid reproduces the cerebellar anomalies associated with autism. 
Neurotoxicology and Teratology, 22, 319-324.
Jyonouchi, H., Sun, S., & Itokazu, N. (2002). Innate immunity associated with 
inflammatory responses and cytokine production against common dietary proteins in 
patients with autism spectrum disorder. Neuropsychobiology, 46, 76-84.
109
Le Poul, E., Loison, C., Struyf, S.E., Springael, J.Y., Lannoy, V., Decobecq, M.E. (2003). 
Functionaly characterization of human receptors for short chain fatty acids and their role 
in polymorphonuclear cell activation. The Journal o f  Biological Chemistry, 278, 25481- 
25489.
MacFabe, D.F., Cain, N.E., Boon, F., Ossenkopp, K.-P., & Cain, D.P. (2011). Effects of 
the enteric bacterial metabolic product propionic acid on object-directed behavior, social 
behavior, cognition, and neuroinflammation in adolescent rats: Relevance to autism 
spectrum disorder. Behavioural Brain Research, 217, 47-54.
MacFabe, D., Cain, D., Rodriguez-Capote, K., Franklin, A., Hoffman, J., Boon, F., et al. 
(2007). Neurobiological effects of intraventicular propionic acid in rats: Possible role of 
short chain fatty acids on the pathogenesis and characteristics of autism spectrum 
disorders. Behavioural Brain Research, 176, 149-169.
MacFabe, D., Rodriguez-Capote, K., Hoffman, J., Franklin, A., Mohammad-Asef, Y., 
Taylor, R., et al. (2008). A novel rodent model of autism: intraventricular infusions of 
propionic acid increase locomotor activity and induce neuroinflammation and oxidative 
stress in discrete regions of adult rat brain. American Journal o f  Biochemistry and 
Biotechnology, 4(2),  146-166.
Morris, R.G.M. (1989). Synaptic plasticity and learning: Selective impairment of learning 
in rats and blockage of long-term potentiation in vivo by the A-Methyl-D-Aspartate 
receptor antagonist AP5. The Journal o f  Neuroscience, 9(9), 3040-3057.
Nakao, S., Moriya, Y., Furuyama, S., Niederman, R., & Sugiy, H. (1998). Propionic acid 
stimulates superoxide generation in human neutrophils. Cell Biology International, 22, 
331-337.
Narita, N., Kato, M., Tazoe, M., Miyazaki, K., Narita, M., & Okado, N. (2002). Increased 
monoamine concentration in the brain and blood of fetal thalidomide- and valproic acid- 
exposed rat: putative animal models for autism. Pediatric Research , 52, 576-579.
Patterson, P.H. (2009). Immune involvement in schizophrenia and autism: Etiology, 
pathology and animal models. Behavioural Brain Research, 204(2), 313-321.
Rorig, B., Klausa, G., & Sutor, B. (1996). Intracellular acidification reduced gap junction 
coupling between immature rat neocortical pyramidal neurons. Journal o f  Physiology, 
490 (pt-1), 31-49.
Sasson, N.J., Turner-Brown, L.M., Holtzclaw, T.N., Lam, K.S., & Bodfish, J.W. (2008). 
Children with autism demonstrate circumscribed attention during passive viewing of 
complex social and nonsocial picture arrays. Autism Research, 1, 31-42.
Saucier, D., Hargreaves, E.L., Boon, F., Vanderwolf, C.H., & Cain, D.P. (1996). Detailed 
behavioral analysis of water maze acquisition under systemic NMDA or muscarinic 
antagonism: Nonspatial pretraining eliminates spatial learning deficits. Behavioral 
Neuroscience, 110, 103-116.
110
Shi, S.R., Cote, R.J., & Taylor, C.R. (2001). Antigen retrieval techniques: Current 
perspectives. Journal o f  Histochemistry and Cytochemistry, 49, 931-937.
Shultz, S. R., MacFabe, D. F., Ossenkopp, K.-P., Scratch, S., Whelan, J., Taylor, R., et al. 
(2008). Intracerebroventricular injection of propionic acid, an enteric bacterial metabolic 
end-product, impairs social behaviour in the rat: Implications for an animal model of 
autism. Neuropharmacology, 54, 901-911.
Shultz, S. R., MacFabe, D. K., Martin, S., Jackson, J., Taylor, R., Boon, F., et al. (2009). 
Intracerebroventricular injections of the enteric bacterial metabolic product propionic acid 
impair cognition and sensorimotor ability in the Long-Evans rat: further development of a 
rodent model of autism. Behavioral Brain Research , 200, 33-41.
Suzuki, K., Nagao, K., Tokunaga, J., Katayama, N., & Uyeda, M. (1996). Inhibition of 
DNA methyltransferase by microbial inhibitors and fatty acids.
Thomas, R. FI., Foley, K. A., Mepham, J. R., Tichenoff, L. J., Possmayer, F., & MacFabe, 
D. F. (2010). Altered brain phospholipid and acylcarnitine profiles in propionic acid 
infused rodents: further development of a potential model of autism spectrum disorders. 
Journal o f  Neurochemistry, 113 (2), 515-529.
Vargas, D. L., Nascimbene, C., Krishnan, C., Zimmerman, A. W., & Pardo, C. A. (2005). 
Neuroglial activation and neuroinflammation in the brain of patients with autism. Annals 
o f  Neurology, 57, 67-81.
Wagner, A. K., Bayir, H., Ren, D., Puccio, A., Zafonte, R. D., & Kochanek, P. M. (2004). 
Relationships between cerebrospinal fluid markers of excitotoxicity, ischemia, and 
oxidative damage after severe TBI: the impact of gender, age, and hypothermia. Journal o f  
Neurotrauma, 21, 125-136.
Wajner, M., Santos, K. D., Schlottfeldt, J. L., Rocha, M. P., & Wannmacher, C. M.
(1999). Inhibition of mitogen-activated proliferation of human peripheral lymphocytes in 
vitro by propionic acid. Clinical Science , 96, 99-103.
Chapter 4:
General Discussion
4.1 “Recovery” in Autism Spectrum Disorders 
Several studies have reported on the concept of “recovery” in autism. While ASDs 
are generally considered to be life-long disorders affecting cognition, language, and social 
behaviour, the severity of these symptoms varies between individuals and also across time 
within individuals (Helt et al., 2008). Herbert and colleagues (2006) noted that there is 
substantial intra-individual variability in autistic individuals in both the nature and severity 
of the characteristic symptoms, and this variability can occur over the short, medium, or 
long term. Helt et al. (2008) describe “recovery” as the loss of the behavioural 
characteristics of ASD, though they acknowledge that this most often does not result in the 
child receiving a label of “normal”. Beyond individual case studies of recovery in autism, 
the long-term outcome in terms of diagnostic stability has not been widely studied and the 
findings that do exist are often varied. For instance, Cox et al. (1999) found that all nine 
children studied who were diagnosed with pervasive developmental disorder (PDD, a 
disorder on the autism spectrum) at 20 months of life retained the diagnosis at 42 months. 
Other studies have reported that a subset of individuals achieved normal levels of 
intellectual and educational functioning following intensive behavioural therapy over a 
number of years (McEachin, Smith, & Lovaas, 1993). Based on Helt et al.’s (2008) 
definition of “recovery” as the loss of characteristic symptomatology, there have also been 
reports of the improvement of ASD symptoms following the removal of certain wheat or 
dairy products from the diet (Jyonouchi, Sun, & Itokazu, 2002). These limited yet 




The purpose of the present studies was to investigate this idea of “recovery” using an 
animal model of ASD. Studies using the PPA rodent model of autism have shown 
behavioural, neuropathological, and biochemical changes in animals resulting from 
treatment with PPA, all of which are consistent with findings from autistic patients 
(MacFabe et al,, 2007; MacFabe et al., 2008; MacFabe, Cain, Boon, Ossenkopp, & Cain, 
2011; Shultz et al., 2008; Shultz et al., 2009; Thomas et al., 2010). Shultz et al. (2009) in 
particular found a unique pattern of perseveratory behaviour using the Morris water maze, 
following PPA treatment. Animals were given three or five single, spaced infusions of 
PPA and tested in the water maze for acquisition and then maze reversal. During reversal 
training, they were unable to learn the new location of the hidden platform due to 
persistent returning to the initial quadrant that held the platform during acquisition. Given 
what is known about the various physiological effects of PPA in humans (Al-Lahham, 
Peppelenbosch, Roelofsen, Vonk, & Venema, 2010; Hara, Haga, Aoyama, & Kiriyama, 
1999; Nakao, Moriya, Furuyama, Niederman, & Sugiy, 1998; Wagner, Bayir, Ren,
Puccio, Zafonte, & Kochanek, 2004), as well as the effects seen in the rodent model of 
autism, it was of interest to investigate the time-course of these effects and whether or not 
they are permanent. Overall, the findings from the present studies suggest that the 
majority of cognitive and neuropathological variables measured return to baseline levels 
following cessation of PPA treatment. There were several instances where animals in 
either the PPA-PBS or PBS-PPA group performed at an intermediate level between PBS- 
PBS controls and PPA-PPA animals on reversal day, such as total distance traveled and 
time spent in periphery for non-pretrained animals and search latency for pretrained 
animals. These interesting findings suggest that there may be differential effects of PPA,
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based on the dose and timing of administration. In the case of the PPA-PBS group, these 
intermediate values, though not statistically significant, might suggest a remaining deficit 
left over from initial PPA treatment. The intermediate performance on some variables 
seen in the PBS-PPA group, however, suggests that two infusions alone of PPA on 
reversal day were not enough to cause the same severity of impairment as seen following 
16 infusions of the compound (in the case of the PPA-PPA group). This would indicate 
that, perhaps there are persisting effects caused by PPA loading, which were not identified 
using the present experimental design.
Further evidence for a return to baseline following cessation of PPA treatment came 
from the finding of a lack of group differences in neuroinflammation in the brains of these 
rodents. Other than an increase in reactive astrocytes seen in the white matter of 
pretrained animals treated with PPA the day prior to perfusion, regardless of initial 
treatment, there were no observed differences in GFAP or Iba-1 staining in any other brain 
area studied. Due to the known neuroinflammatory response in the PPA model of autism 
(MacFabe et al., 2007; MacFabe et ah, 2008), it would be appropriate to cautiously 
suggest a return to baseline in the inflammatory response of these glial cells following 
cessation of treatment with PPA. It could be the case that the astroglial inflammation 
induced in the white matter following acute treatment with PPA was more extensive than 
the inflammation induced in other areas. It has been shown that ASD patients have an 
increased white matter volume compared to controls (Herbert, 2005) and this could result 
from an inflammatory response.
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4.1.1 Possible Mechanisms
The underlying mechanism(s) of the effects of PPA on various cognitive, 
behavioural, and neuropathological effects is unknown. The effects seen in the current 
study appear to return to baseline after a brief period of no infusion. This suggests, as has 
been shown by other studies using the model (MacFabe et al., 2007), that many of the 
effects of PPA are transient. The transient nature of these alterations implicates the action 
of environmentally responsive disease mechanisms, which would also explain the 
fluctuations seen in autistic symptomatology. As previously mentioned, it is possible that 
PPA is affecting gene expression. MacFabe and colleagues (2007) found increased 
immunoreactivity of the phosphorylated form of cyclic AMP responsive binding protein 
(pCREB), which, in its activated form, is involved in altering the expression of genes 
involved in learning and memory. Beyond this, Herbert et al. (2006) found a number of 
environmentally responsive genes that overlap with known autism linkage regions. This 
set of genes included, but was not limited to, those involved in cell signaling, homeostasis, 
metabolism, immune/inflammatory response, and oxidative stress/metabolism. Another 
possible mechanism for these behavioural effects of PPA was highlighted in a study done 
by Thomas and colleagues (2010) using the PPA model of autism. The authors found 
alterations in the lipid profiles of rodents who had been treated with PPA twice a day for 
seven days that were consistent with alterations seen in the lipid profiles of autistic 
patients (Bell, Sargent, Tocher, & Dick, 2000). Similarly, studies and anecdotal reports 
from parents of autistic children have suggested improvements in the general health and a 
reduction in core symptoms in ASD patients following essential fatty acid 
supplementation (Bell, MacKinlay, Dick, MacDonald, Boyle, & Glen, 2004; Richardson,
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2006). The lipids showing alterations in the PPA rodent model included those involved in 
cell-to-cell signaling, membrane fluidity, and energy metabolism (Thomas et al., 2010). 
Changes affecting the ability of cells to communicate with one another (i.e., changes in 
membrane fluidity, cell signaling, and the uncoupling of gap junctions) could all affect 
processes involved in learning and memory, as was seen in the present experiments. 
However, it is not clear precisely which of the diverse effects of SCFAs are responsible 
for the observed characteristics in the model.
4.2 Limitations and Future Directions
While the current study has contributed to the PPA rodent model of autism by 
beginning to investigate the time course of the effects of the compound, there is still a 
great deal of work to be done in this area. As with any study, there were limitations, 
leading to the inability to draw certain, definite conclusions from the collected data. 
Identification of these limitations can help to interpret the data, as well as lead to further 
areas of study using the model.
4.2.1 Convulsive Activity
Slightly less than one third of the animals in the two studies presented here displayed 
convulsive activity in the water maze during acquisition. Due to the potential interference 
that convulsive activity may have caused in the animals’ ability to learn the maze, data 
from these rats were removed from all water maze analyses. Although the presence of 
convulsive activity does not guarantee the occurrence of seizure activity, these data were 
removed to be conservative. In removing these data, the remaining data that were 
analyzed came from animals that were essentially resistant to PPA-induced convulsions. 
Animals that were resistant to the demonstrated electrophysiological effects of PPA
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(MacFabe et al., 2007) were selected for in this analysis and this cannot be ruled out as a 
potential confound. Similarly, although many animals did not exhibit outward signs of 
convulsive activity, this does not necessarily mean that they did not experience seizure 
activity. This can only be confirmed through EEG.
Future studies might address this issue by experimenting with a lower dose of PPA 
that would cause fewer convulsions. The study by Shultz et al. (2009), which used three 
or five single, spaced ICV infusions prior to testing, reported no convulsive activity during 
water maze training. This suggests that altering the infusion schedule, either the frequency 
or dose of PPA administration, can potentially alter the level of convulsive activity seen in 
the model. Flowever, the current studies employed the 7-day infusion schedule in order to 
be consistent with the previous work done using the PPA rodent model of autism (Thomas 
et al., 2010). Similarly, the occurrence of convulsive activity in these experiments lends 
validity to the model in that seizure disorder and epilepsy are often comorbid with ASD 
(Besag, 2004; Herbert et al., 2006) and other neurodevelopmental disorders, particularly 
those involving more severe cognitive and/or developmental delay (Sunder, 1997). In 
fact, it is possible that this electrophysiological activity that has been shown to occur in 
these patients could be contributing to the cognitive deficits that are present in this 
population.
4.2.2 Future Studies
Intracerebroventricular infusion of enteric SCFAs, such as PPA, in rodents is 
becoming a promising animal model for investigating the various behavioural and 
neuropathological aspects of ASD (MacFabe et al., 2007; MacFabe et al., 2008; MacFabe 
et al., 2011; Shultz et al., 2008; Shultz et al., 2009; Thomas et al., 2010). The findings of
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the present study are consistent with ASD, and offer further support of PPA administration 
as an animal model of autism. Further work with the model should examine the time 
course of the effects of SCFAs in adolescent rats. ASD is a lifelong disorder, making it 
important to study at various different points of development. Similarly, it is necessary to 
conduct further studies aimed at identifying possible mechanisms that are responsible for 
these effects. Identification of a mechanism would be a step towards isolating potential 
biomarkers and eventually treatments for this disorder. Based on the promising findings 
of altered lipid profiles in the model similar to those seen in ASD patients (Thomas et al., 
2010), future work should explore the lipid profiles over an extended time course, such as 
the one used in the present studies. It would be interesting to see if the alterations in the 
lipid profiles caused by PPA administration return to baseline after a period of time 
without exposure to the compound in the same way that behavioural and 
neuropathological alterations did in the present studies. These studies are ongoing using 
brain tissue obtained from the present study. Overall, the PPA rodent model of autism has 
proved to be a valid model for studying the disparate symptoms, comorbidities, and 
biomarkers found in ASD, and there is a great deal more work that can be done to 
continue to add to what is known about the disorder.
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